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MATERIALS OF SYMPOSIUM AND SUMMER SCHOOL 
“FUNDAMENTAL PRINCIPLES OF CANCER BIOTHERAPY”, 
MAY 21–23, 2018, KYIV, UKRAINE
The International Scientific Symposium “Funda­
mental Principles of Cancer Biotherapy” was held 
on May 21–23, 2018 in Kyiv, Ukraine. It was organized 
by R.E. Kavetsky Institute of Experimental Patho­
logy, Oncology and Radiobiology (IEPOR) of the 
National Academy of Sciences of Ukraine (NASU). 
The symposium was supported by the VACTRAIN 
project (TWINNING on DNA­based Cancer Vaccines, 
No 692293) in the frame of the European Union’s Ho­
rizon 2020 Research and Innovation Program.
At the symposium, the invited speakers and young 
researchers from Ukraine, Poland, Latvia, India and 
Sweden presented the latest data of their studies. 
The main focus of the meeting was cancer biotherapy, 
including discussion on the new targets and metho­
dologies. More than 70 researchers took part in the 
work of this conference. At the opening speech, the 
Director of R.E. Kavetsky IEPOR of NASU, Academician 
of NASU Vasyl Chekhun gave a brief overview on IEPOR 
research and collaborations. He also mentioned that 
the VACTRAIN grant provided the opportunities 
of the professional growth for the young generation 
of research fellows. Dr. Chekhun welcomed all the at­
tendees in Kyiv, especially this year, when we celebrate 
the centenary of the Ukrainian Academy of Sciences. 
The conference venue, a Great Conference Hall of the 
NASU, was an obvious choice for this event.
Galina Selivanova (Sweden) presented a new 
conception, concerning a guardian of a genome — 
the p53 protein. Galina told about two faces of p53, 
so called “the p53­healer” and “the p53­killer”. It was 
extremely important to learn about successful clinical 
trials of the novel anticancer medicine, based on ac­
tivation of the p53 protein. Liudmyla Drobot (Ukraine) 
spoke about plasticity of cancer cells, especially about 
an amoeboid stage of epithelial­to­mesenchymal 
transition (EMT) that helps tumors cells to migrate 
and metastasize. Elena Kashuba (Ukraine) continued 
the EMT topic and elucidated a role of mitochon­
drial ribosomal protein S18­2 (MRPS18­2) in this 
process in prostate cancer. During the conference, 
new directions of cancer therapy were discussed 
by Volodymyr Shlyakhovenko, Artem Tykhomyrov, Ok­
sana Skachkova and Olha Karaman (all from Ukraine). 
Andrey Alexe yenko (Sweden) spoke about systems 
biology — an important part of tumor biology. Phi­
losophy and history of cancer research was discussed 
by Chacnhal Mitra (India).
The poster sessions with vivid discussions on the 
different topics related to cancer therapies were held 
during these two days of the conference (see se­
lected abstracts). Cancer therapy and the problems 
of personalized cancer therapy are also in the spot 
of the interest of the society. A journalist from “Health 
of Ukraine” newspaper was present at the conference 
and we expect to see an article soon.
SELECTED ABSTRACTS
FUNCTIONAL ACTIVITY  
OF THE NADH-DEPENDENT REDUCTASE 
SYSTEM IN A LIVER MICROSOMAL FRACTION 
IN RATS WITH GUERIN’S CARCINOMA 
UNDER CONDITIONS OF ESSENTIAL 
NUTRIENTS ADMINISTRATION
V. Borschovetska*, O. Ketsa, M. Marchenko
Yuriy Fedkovych Chernivtsi National University, 
Chernivtsi, Ukraine
*E-mail: v.borschovetska@chnu.edu.ua
Background: The liver monooxygenase system 
(MOS) plays a major role in the metabolism of im­
portant endogenous substrates as well as in bio­
transformation of xenobiotics. However, the growth 
of tumor impairs the MOS functioning that results 
in the increase of the intracellular concentration 
of the free radical molecules. Free radicals attack 
important macromo lecules, leading to cell damage 
and homeostatic disruption. It was shown already 
that essential nutrients, such as retinoids and polyun­
saturated fatty acids, play an important role in cancer 
prevention. These compounds are recognized also 
by their anti­proliferative and anti­oxidative activity, 
but it is unknown how they affect MOS in the liver 
of tumor­bearing animals.
The aim of the study was to determine the acti­
vity of the NADH­dependent reductase system in the 
microsomal fraction and the superoxide radical gene­
ration by this system under conditions of essential 
nutrient administration.
Methods: As a model of malignant tumor growth, 
Guerin’s carcinoma was employed. ω­3 PUFAs and 
retinoids were administered by gavage for 4 weeks 
prior to the carcinoma implantation and then for 
the entire duration of tumor growth. The daily dose 
of ω­3 PUFAs was 120 mg/kg of a body mass. Reti­
noids were administered as the retinyl ester at a dose 
of 3000 IU. Microsomal fraction was obtained by dif­
ferential centrifugation. A catalytic activity of NADH­
cytochrome b5 reductase (CYB5R), cytochrome 
b5 (CYB5) and P450 content (CYP), and also the rate 
of generation of superoxide anion radical by compo­
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nents of the reductase chain were assessed in these 
fraction, using a spectrophotometric assay.
Results: NADH­dependent CYB5R activity in the 
liver microsomal fraction in rats with Guerin’s carci­
noma increases by 29% in comparison with a control 
group. The significant increase in the rate of gen­
eration of superoxide anion radical by components 
of the reductase chain (4.6 fold) indicates the 
change of the electron transport in the reductase 
chain. CYB5R transmits electrons not to CYB5, but 
to the oxygen molecule, followed by the formation 
of reactive species. The high CYB5R activity and the 
enhanced generation of O2•­ lead to a 2­fold decrease 
in the content of the membrane­associated CYB5. 
Administration of pharmacological doses of retinoids 
prior to and post­implantation of the tumor leads 
to a reduction of functional activity of the NADH­
dependent reductase system in the microsomal 
fraction and decrease of CYP content by 48%. The 
generation of a large amount of hydroxyl metabo­
lites of retinol further contributes to the damage 
of liver. The ω­3 PUFAs supplementation, which 
has anti­oxidative activity and can repair damaged 
membranes by embedding into them, has some 
stabilizing effects. However, the complete recovery 
of the studied activities to the corresponding indica­
tors of control group was not shown.
Conclusions: The obtained results indicate that 
administration of pharmacological doses of the vitamin 
A prior to grafting carcinoma cells impairs the func­
tional activity of NADH­dependent reductase system 
in the microsomal fraction of the liver. The ω­3 PUFAs, 
as components of membranes, help to maintain the 
functional state of the MOS components in the endo­
plasmic reticulum.
TUMOR-INFILTRATING LYMPHOCYTES, 
HYPOXIA AND CANCER-ASSOCIATED 
ADIPOCYTES IN PRIMARY TUMORS 
IN PATIENTS WITH GASTRIC CANCER 
AND OVERWEIGHT
L. Bubnovskaya1, *, L. Gumenyuk1, 
V. Mikhailenko1, S. Merentsev2, D. Osinsky2
1R.E. Kavetsky Institute of Experimental Pathology, 
Oncology and Radiobiology, NAS of Ukraine,  
Kyiv, Ukraine
2Kyiv City Clinical Oncological Center,  
Kyiv, Ukraine
*E-mail: osinskysp12@ukr.net
Background: Obesity has been linked to more ag­
gressive characteristics of the major common cancers, 
including breast and prostate cancer, colorectal, endo­
metrial, esophageal, pancreatic and renal cell cancer. 
The growth and metastasizing of solid tumor growth re­
quire the interaction of tumor cells with the surrounding 
tissue. Due to the ubiquitous nature of adipose tissue, 
many types of solid tumors grow in the close proximity 
or direct contact with adipocytes and adipose­asso­
ciated stromal and vascular components. Adipocytes 
modulate the tumor microenvironment by promoting 
angiogenesis, affecting immune cells and altering me­
tabolism to support growth and survival of metastatic 
cancer cells. During their interaction with cancer cells, 
adipocytes dedifferentiate into pre­adipocytes or are 
reprogrammed into cancer­associated adipocytes 
(CAA) that secrete adipokines, stimulating adhesion, 
migration, and invasion of tumor cells.
At the same time, the stromal components of tumor 
microenvironment, such as tumor­infiltrating lympho­
cytes (TILs) and hypoxia are also the crucial factors 
for tumor growth. However, the very limited data are 
reported, describing possible associations between 
these factors and CAA in patients with gastric can­
cer (GC) and with overweight, in particular.
The aim: We wanted to examine the dependence 
between the number TILs, CD8+ and CD45RO+ T lym­
phocytes, hypoxia levels, the CAA density and a body 
mass index (BMI) in GC patients.
Methods: Expression of CD8, CD45RO and 
perilipin (PLIN, a marker for viable adipocytes) was 
assessed by immunohistochemistry; hypoxia levels 
in tumor was evaluated by 31NMR spectroscopy; BMI 
was calculated. 94 patients with primary GC were 
diagnosed and treated at the Kyiv City Clinical On­
cological Center. No chemotherapy or radiation prior 
to surgery was conducted. Tumors were classified 
and staged, according to the 2002 version of the 
UICC staging system. All patients were thoroughly 
informed about the study that was approved by the 
local ethics committee.
Results: 36.6; 58.6 and 88.4% of patients with 
BMI < 25, 25 < BMI < 30, BMI > 30 showed a high 
CAA density in tumors, respectively. Median number 
of the CAA was 26.5%. The probability of the high 
density of CAA in tumors of patients with BMI > 30 was 
increased by a factor 11 (OR 11.01, χ2 = 12.9, 95% 
CI 28.933–5.749, р < 0.001) in comparison with 
patients with BMI < 25. Under severe and moderate 
hypoxia (PME < 1.4) in tumors the high CAA density 
was detected in 71.4; 6.8 and 91.7% of patients with 
BMI < 25, 25 < BMI < 30 and BMI > 30, respectively. 
57.1; 42.8 and 16.6% of patients with BMI < 25, 25 < 
BMI < 30 and BMI > 30 had a high number of TILs 
in tumor, respectively. The median number of CD8+ 
and CD45RO+ cells was 34.4 and 36.4%, respectively. 
When tumors showed the high CAA density, then 43.1; 
32.7 and 20.8% of CD8+ T cells and 43.8; 28.7 and 
22.9% CD45RO+ T cells was detected in tumors 
of patients with BMI < 25, 25 < BMI < 30, BMI > 30, 
respectively. The TILs density decreased significantly 
in patients with BMI > 30 (OR = 4.51, χ2 = 4.38, 95% 
CI 10.486–1.916, p < 0.05) as compared with patients 
with BMI < 30.The probability of the presence of the 
low number of CD8+ T cells in tumor was increased 
by the factor of 5.0, when severe and moderate hy­
poxia was detected (p = 0.046).
Conclusions: The elevated BMI values were con­
sistently associated with the high CAA number, as well 
as with decrease of the number of CD8+ and CD45RО+ 
Т cells in GC, but not with hypoxia levels.
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EFFECT OF LACTOFERRIN ON LEVELS 
OF ESSENTIAL ELEMENTS IN ANIMALS 
WITH SENSITIVE AND RESISTANT 
WALKER-256 CARCINOSARCOMA
V. Chekhun1, Yu. Lozovskaya1, *, 
I. Andrusyshyna2, N. Lukyanova1, I. Todor1
1R.E. Kavetsky Institute of Experimental Pathology, 
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Background: It is known that the development 
of hormone­dependent tumors, including breast 
cancer (BC), is accompanied by an imbalance of ho­
meostasis of microelements (ME), which affects the 
change in the catalytic activity of enzymes, regulation 
of hormones, growth factors and the content of trans­
porting proteins. It is shown that the most informative 
for the estimation of antagonistic and synergistic in­
teractions between ME is not only assessment of their 
content, but also analysis of their ratio. However, there 
is practically no data on the correction of mineral me­
tabolism during malignant process with the use of iron 
and copper­binding protein, lactoferrin (LF).
The aim: To investigate the content of Fe, Cu, Zn, 
Ca and Mg in blood serum (BS) and tumor tissue (TT) 
of animals with Walker­256 carcinosarcoma with dif­
ferent sensitivity to doxorubicin (DOX) treated with 
exogenous LF or its combination with DOX.
Methods: In BS and TT of experimental animals, 
we have analyzed ME content after administra­
tion of LF at concentrations of 1 and 10 mg/g. The 
change in ME composition in BS and TT of animals 
with DOX­resistant carcinosarcoma after administra­
tion of 10 mg/g LF, DOX, or LF and DOX combination, 
was determined. The content of Cu, Zn, Mg, Ca and 
Fe in BS and TT was determined by the atomic emis­
sion spectral method, while Fe content in the BS was 
analyzed using biochemical method.
Results: It was shown that administration 
of LF in a concentration of 1 mg/g did not change 
ME content in BS of animals with sensitive carcino­
sarcoma compared with control, while in a concen­
tration of 10 mg/kg LF caused 1.5–2­fold decrease 
in the content of Fe, Cu, Ca in the BS and 1.2­fold 
increase of the content of Mg and Zn. The admini­
stration of LF at 1 or 10 mg/kg decreased the Cu/
Zn ratio (1.44 and 0.52) and Ca/Mg ratio (3.23 and 
2.21) in the BS of treated animals compared to control 
values (2.04 and 4.10). However, LF in a concentration 
of 1 mg/g caused 1.5­2­fold decrease in TT content 
of Fe, Cu, Ca against the background of unchanged 
Zn and Mg content. The administration of LF in concen­
trations of 1 and 10 mg/kg caused a decrease in Cu/
Zn ratio (0.15 and 0.14) and Ca/Mg ratio (0.23 and 
0.20) in TT, compared with the control (0.2 and 0.37, 
respectively). In BS of animals with DOX­resistant car­
cinosarcoma, administration of LF in a concentration 
of 10 mg/g resulted in a 1.2 to 1.5­fold decrease in the 
ME content, except for Zn, which caused a decrease 
in Cu/Zn ratio (1.52) and Ca/Mg ratio (4.27) com­
pared with the control values (2.27 and 5.16). Sepa­
rate administration of DOX caused a decrease in the 
BS content of all ME by 1.3 times along with a 1.2­fold 
increase in Fe content. The most pronounced changes 
in the content of ME in the BS of these animals were 
detected in the case of a combined action of LF and 
DOX: 1.5­2­fold decrease of the content of Fe, Cu and 
Ca at the background of 1.2­fold increase of Zn and 
Mg content of, which caused a decrease in Cu/Zn ratio 
(1.50) and Ca/Mg ratio (4.03). Resistant TT showed 
a similar nature of ME changes, with the most pro­
nounced effect in the case of the combined action 
of LF and DOX, which was reflected in the maximal 
decrease in Cu/Zn ratio (0.14) and Ca/Mg ratio (0.21) 
compared to the control values (0.18 and 0.33).
Conclusions: It was shown that the administration 
of LF in concentrations of 1 and 10 mg/kg to animals 
with DOX­sensitive Walker­256 carcinosarcoma 
changed ME composition and ME ratio in BS and TT, 
with a more pronounced effect in the cases of higher 
LF dose. It was found that the combined effect 
of LF and DOX caused the maximal decrease in Cu/
Zn and Ca/Mg ratio in BS and TT of animals with 
DOX­resistant carcinosarcoma, evidencing on inhibi­
tion of the activity of matrix metalloproteinases and 
epithelial­mesenchymal transition.
DEVELOPMENT, ENGINEERING 
AND PHYSICAL PROPERTIES 
OF A LIPOSOMAL FORM OF THE CYTOTOXIC 
LECTIN FROM B. subtilis B-7025
O. Dvorshchenko*, G. Didenko, O. Kruts, 
A. Krasnoplakhtych
R.E. Kavetsky Institute of Experimental Pathology, 
Oncology and Radiobiology, NAS of Ukraine,  
Kyiv, Ukraine
*E-mail: dos031077@gmail.com
Background: Methods of antitumor biotherapy 
are widely used for a standard treatment of cancer 
patients. An important part of biotherapy is antitu­
mor vaccines, which are often included in treatment 
regimens to prevent disease recurrence and metas­
tasizing. In our previous studies, we have shown that 
the use of antitumor vaccines, produced from tumor 
cells with the addition of the cytotoxic lectin produced 
by B. subtilis B­7025 increased medium life expec­
tancy of experimental animals inhibiting the growth 
of the primary tumor node and decreasing meta­
stasizing. Recently, it was demonstrated that the use 
of pharmaceutical drugs in liposomal forms changed 
dramatically their pharmacokinetics and therapeutic 
efficacy. We hypothesize that the liposomal form of an­
titumor vaccine could significantly increase the immu­
nogenicity of the antigenic component of the vaccine. 
This might be due to unique properties of liposomes, 
protecting the components of antitumor vaccines 
from biodegradation. So, it should be easier to create 
a vaccine depot at the injection site and deliver it to the 
peripheral lymph nodes.
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The aim: To synthesize the liposomal form of the 
cytotoxic lectin isolated from B. subtilis B­7025 and 
characterize its physical properties.
Methods: The liposomal form of the cytotoxic 
lectin from B. subtilis B­7025 was synthesized by the 
liposome hydration method [1]. Physical characte­
ristics of synthesized liposomes are defined on Zeta­
sizer Nano ZS (Malvern Panalytical). The efficiency 
of lectin encapsulation into liposomes was determined 
by the concentration of free protein in a supernatant 
at a wavelength of 280 nm using NanoDrop™ 1000 (de­
scribed in [1]).
Results: A median size of unloaded liposomes was 
151.7 ± 55.2 nm, the Z­potential was −20.5 mV and 
the conductivity was 14.1 mS/cm. The average size 
of liposomes loaded with the cytotoxic lectin was 
314.8 ± 113.0 nm, the Z­potential had three peaks: 
29.8 mV (49.1% of liposomes), −41.3 mV (32% of li­
posomes), and −108 mV (16.7% of liposomes), and 
conductivity was 25.4 mS/cm. The effectiveness 
of encapsulation of the cytotoxic lectin at the moment 
of synthesis was 75.89%. The leakage factor on the 1­, 
4­, 7­, and 15­day after synthesis acquired negative 
values: −5.89%, −24.56%, −19.16% and −25.84%, 
respectively. We suppose that the reduced concentra­
tion of the free lectin could be explained by the ability 
of lectin to form inter­protein complexes.
Conclusions: The liposomal form of the cytotoxic 
lectin from B. subtilis B­7025 was synthesized and its 
physical properties were characterized.
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I. Fridrihsone1, *, D. Mezale1, I. Strumfa1, 
A. Vanags2, E. Pankova3, 4, S. Petkov5, 
P. Podshwadt5, 6, E. Starodubova4, J. Jansons7, 8, 
M. Isaguliants5, 7
1Department of Pathology, and 2Department 
of Surgery, Riga Stradins University, Riga, Latvia
3Gamaleya Research Center of Epidemiology 
and Microbiology, Moscow, Russia
4Engelhardt Institute of Molecular Biology, Moscow, 
Russia
5Microbiology and Tumor Biology Center,  
Karolinska Institutet, Stockholm, Sweden
6Ulm University Hospital, Ulm, Germany
7Kirchenstein Institute of Microbiology and Virology, 
Riga Stradins University, Riga, Latvia
8Biomedical Research and Study Center,  
Riga, Latvia
*E-mail: ilze.fridrihsone@rsu.lv
Introduction: The 4T1 breast carcinoma is a highly 
tumorigenic and invasive transplantable tumor cell 
line resembling human triple negative breast cancer. 
It can spontaneously metastasize from the primary 
tumor to multiple distant sites including lymph nodes, 
liver, lung, brain, and bone (Pulaski et al., 2001). Thus, 
4T1 is a relevant tumor model including the gene­
ral field of immunization studies in oncology as well 
as lung metastases, in particular.
The aim of the present study was to characterize 
capacity of breast carcinoma cells 4T1 to metastasize 
to the lung by tumor burden evaluation after experi­
mental introduction of different HIV genes in cell line 
and/or immunization.
Methods: Lung samples (n = 32) were analysed 
from mice transplanted with 4T1luc2 adenocarcinoma 
cells expressing variants of HIV­1 FSU_A enzyme 
with and without drug resistance mutations. Twenty 
four mice were transplanted with 4T1luc2 express­
ing proteases (PR) (PR­DNA immunized 15, naïve 9). 
Controls (n = 8) received parental 4T1luc2 adeno­
carcinoma cells. Metastases were diagnosed and 
evaluated in formalin­fixed, paraplast­embedded 
liver tissues. For each mouse, the area of tumor me­
tastases was quantified in five high power (400x) mi­
croscope fields of haematoxylin­eosin­stained slides 
by computer­ assisted morphometry using specialized 
NIS­Elements software (Nikon, Tokyo, Japan). IBM 
SPSSv23 was applied for statistical analysis, includ­
ing descriptive assessment as detection of mean 
values, standard deviation (SD) and 95% confidence 
interval (CI). 
Results: Lung metastases were found in lungs 
of 1/8 PR(Ai) (12.5%; CI 2.2–47.0); 1/8 PR(A2mut) 
(125%; CI 2.2–47.0); 2/8 PR(A3mut) implanted mice 
(22.2%; CI 6.3–54.7); and 3/8 in control group (37.%; 
CI 13.6–69.4). PR(Ai) immunized mice developed 
metastasis in 1/8 (12.5%; CI 2.2–47.0); PR(A2mut) 
immunized, in 0/8 (0%; CI 0–32.4); and PR(A3mut) 
immunized, in 2/8 (22.2%; CI 6.3–54.7) examined 
cases. The mean size of PR(Ai) metastases was 
0.03 mm2 (SD ± 0.02), 0.03 mm2 (SD ± 0.02) of PR(Ai) 
immunized and 0 mm2 of naïve; PR(A2mut), 0.02 mm2, 
0 mm2 of PR(A2mut) immunized and 0.02 mm2 of naïve 
mice metastases; PR(A3mut), 0.03 mm2 (SD ± 0.02), 
0.03 mm2 (SD ± 0.02) of PR(A3mut) immunized and 
0 mm2 of naïve; and 0.01 mm2 (SD ± 0.01) in naïve 
4T1luc2 implanted mice.
Conclusions: Number of subjects with metasta­
ses among HIV DNA­immunized mice implanted with 
HIV­expressing tumors was insignificantly higher than 
among naïve animals (3/15 vs 1/9, p < 1.0). DNA­
immunization with PR does not protect against lung 
metastases. Further histological evaluation of lung 
metastases needs to be done.
TUMOR-ASSOCIATED ADIPOCYTES 
AND MINIMAL RESIDUAL DISEASE 
IN GASTRIC CANCER
I. Ganusevich1, *, V. Zvirych2, A. Burlaka1
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Background: It is known that some tumors 
(gastric cancer (GC), breast, colon and ovarian tu­
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mors) develop at sites of anatomical accumulation 
of an adipose tissue. A modified redox state of the 
tumor is a factor that damages the mitochondria 
of adipocytes and re­programs them into tumor­
associated adipocytes (TAAs). The latter are char­
acterized by pro­oncogenic properties. TAAs are 
an important source of adipocytes and energy for 
the tumor; hence, studying the mechanisms of cell 
and metabolic symbiosis of adipocytes and tumor 
cells opens up the new therapeutic and diagnos­
tic possibilities. In particular, the prediction of the 
course of micro­metastasizing, taking into account 
the number of TAAs, will allow an individualized anti­
tumor therapy for patients with overweight and with 
a minimal residual disease (MRD).
The aim: To characterize the relationship between 
the number of TAAs and body mass index (BMI), 
clinical and pathological characteristics, the rate 
of generation of superoxide radicals (SR), an activity 
of gelatinases (matrix metalloproteinases­2 and ­9) 
in tumor adipose tissue (TAT), the number of dissemi­
nated tumor cells in the bone marrow and the survival 
of patients with GC.
Methods: Immunohistochemistry, zymography, 
EPR spectroscopy, statistical (Student t­test, Spear­
man correlation analysis, Kaplan — Mayer survival 
analysis).
Results: A reliable correlation was found between 
the number of TAAs in the tumor and the BMI of the 
patients with GC (rho = 0.41; p = 0.032). The content 
of TAAs increases with the growth of tumor size and 
in patients with the category of pT4 — this value was 
1.3 fold (p < 0.05) higher than in the tumors of pT1 pa­
tients. In patients with both regional and distant 
metastases, number of TAAs in tumors was higher 
than in patients without metastases. A large number 
of TAAs in the tumor is also associated with a high rate 
of SR generation and a higher activity of gelatinases. 
On the other hand, the high number of TAAs is as­
sociated with the presence of the distant metastases 
of GC. For M1 patients, the higher rates of SR and 
the total activity of gelatinases in TATs were detected 
(in 83 and 64%, respectively). It makes 30% increase 
in the TAA number in the tumor compared with M0 pa­
tients. Patients with less than 26.5% of TATs in the 
tumor live reliably longer and have a 2.9­fold lower 
risk of adverse illness, compared with patients with TAT 
number exceeding 26.5%. For the group of patients 
with the existing duodenal ulcer, no reliable association 
between survival and TAT number was detected (p = 
0.6203). However, we found such association in pa­
tients without micro­metastases (p = 0.005).
Conclusions: Dysfunctional adipose tissue, one 
of the hallmarks of the imbalance of the redox state, 
is a modifier of the tumor microenvironment, involved 
in formation of its aggressive phenotype. The number 
of TATs is associated with tumor growth and metasta­
sizing. Hence, it can be used as a marker for control 
of MRD formation and the course of GC in overweight 
patients.
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Background: Prostate cancer is one of the most 
common cancers in men worldwide. It is known 
as a very heterogeneous and complicated cancer 
type. Many genetic, epigenetic, transcriptomic and 
metabolomics alterations have oncogenic effect 
on prostate carcinogenesis. Therefore, the molecular 
characteristics of individual cancers are necessary 
for both, a diagnosis and prognosis and also for the 
deve lopment of various cancer therapies. We have se­
lected 30 genes that are associated with the epithelial­
me senchymal transition, and also genes, encoding 
several hormonal receptors and metabolic enzymes, 
related to prostate carcinogenesis. We determined 
alterations in a gene expression pattern and also the 
presence of the TMPRSS2: ERG fusion in prostate 
tumors.
The aim was to analyze the expression patterns 
of the cancer­associated genes in benign and malig­
nant prostate tumors, compared with conventionally 
normal tissues (CNT). We wanted to relate these pat­
terns to PTEN expression levels, presence or absence 
of the TMPRSS2/ERG fusion, and also clinical and 
pathological characteristics of tumors.
Methods: The relative expression levels (RE) 
of 47 prostate cancer­associated genes were ana­
lyzed in 37 freshly frozen samples of prostate cancer 
tissues of different tumor stages and Gleason scores, 
compared with the 37 paired CNTs and 20 samples 
of prostate adenomas, using quantitative PCR.
Results: We have found that 13 genes were ex­
pressed differently in adenomas and malignant pros­
tate tumors (AR, PTEN, VIM, MMP9, KRT18, PCA3, 
HOTAIR, SCHLAP1, ESR1, GCR, PRLR, SRD5A2, VDR). 
We have shown that PTEN RE decreased in an ad­
enocarcinoma group as well as in CNTs, compared 
with adenomas. 54.0% of adenocarcinomas, 48.6% 
of CNTs and 25.0% of adenomas were characterized 
by the low PTEN RE. We have found that 9 genes dif­
ferentially expressed in groups with the different levels 
of PTEN, namely ESR1, GCR, KRT18, MMP2, MMP9, 
SRD5A2, VIM, PCA3 and HOTAIR. We have shown that 
9 genes (AR, ESR1, KRT18, MMP9, PRLR, SRD5A2, 
PCA3, HOTAIR and SCHLAP1) expressed differently 
in adenomas, CNTs and adenocarcinomas, depending 
on the presence or the absence of the TMPRSS2/ERG 
fusion. We have identified 14 differentially expressed 
genes in groups of various tumor stages (AR, KRT18, 
MMP9, VIM, PCA3, HOTAIR, SCHLAP1, ESR1, GCR, 
INSR A, IGFR tr, PRLR, VDR, SRD5A2) and 11 genes 
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that were expressed differently in tumors of various 
Gleason score (AR, CDH1, KRT18, MMP9, OCLN, 
PCA3, HOTAIR, SCHLAP1, ESR1, VDR, SRD5A2).
Conclusions: We have identified alterations 
in expression of cancer­associated genes in prostate 
tumors, depending on the tumor stage, Gleason score, 
levels of PTEN and the presence of the TMPRSS2: 
ERG fusion. These findings would help to characterize 
the molecular profiles of prostate tumors with the aim 
to improve the anti­tumor therapy.
FREEZING CONDITIONS DETERMINE 
PRESERVATION OF ANTIGENIC 
CHARACTERISTICS OF CANCER CELLS
A. Goltsev*, N. Bondarovich, N. Babenko, 
Yu. Gaevskaya
Institute for Problems of Cryobiology 
and Cryomedicine, NAS of Ukraine, Kharkiv, Ukraine
*E-mail: cryopato@gmail.com
Background: Testing of new antitumor drugs, the 
creation of vaccines as immune therapeutic agents 
for the treatment of oncological diseases requires the 
development of adequate methods to store the tumor 
cells. There is always a possibility that expression 
of markers in tumor samples after cryopreservation 
could be altered.
The aim was to evaluate a spectrum of antigens 
of Ehrlich carcinoma (EC) cells after the serial freeze­
thawing, using a variety of cryopreserving media.
Methods: The experiments were performed, using 
Balb/C mice. The primary culture of EC was grown for 
7 days in a peritoneal cavity (PC) of mice. Afterwards, 
the cells were removed from the PC, washed and 
after centrifugation were frozen down: first to −80 °C, 
at a rate of 1 °C/min and then cells were plunged 
into liquid nitrogen, using several cryopreserving 
media, i.e. Ringer phosphate buffer (RPB), ascites 
and DMEM with 10% DMSO. Immediately after thaw­
ing, the number of cells in the sample was counted 
as well as their viability was assessed by staining with 
propidium iodide. A sub­population composition was 
determined, using monoclonal antibodies against 
CD44 and CD24 (BD Biosciences, USA) and a FACS 
Calibur flow cytometer (BD, USA). Cells not subjected 
to freeze­thawing served as a control.
Results: We found that the selected cooling rate 
provided the preservation of the cells in the sample 
at the control level, regardless of the freezing medium. 
The viability of cryopreserved samples in RPB was 
42.05 ± 4.12%, in ascites 65.42 ± 2.67% and in DMEM 
+ 10% DMSO 89 ± 3.76%. Cryopreservation of EC cells 
using RPB and ascitic fluid led to a decrease in the 
content of CD44+ subpopulations, and an increase 
in CD24+ positive subpopulations. The use of DMEM 
+ 10% DMSO ensured the safety of all the detectable 
subpopulations at the control level, including CD44­
high cells, the main candidates for cancer stem cells.
Conclusions: The obtained data emphasize the 
need of a careful selection of preservation conditions, 
determining the preservation of the antigen spectrum 
of tumor cells during their long­term storage.
CD150/SLAMF1 RECEPTOR IS INVOLVED 
IN REGULATION OF CHRONIC LYMPHOCYTIC 
LEUKEMIA PATHOBIOLOGY
I. Gordiienko*, L. Shlapatska, V. Kholodniuk, 
L. Sklyarenko, S. Sidorenko
R.E. Kavetsky Institute of Experimental Pathology, 
Oncology and Radiobiology, NAS of Ukraine,  
Kyiv, Ukraine
*E-mail: imgordiienko@gmail.com
Background: Despite the homogeneous CD150/
SLAMF1 expression on subpopulations of normal 
B cells it is differentially expressed on the cell surface 
of malignant B cells including chronic lymphocytic leu­
kemia (CLL) B cells. High cell surface CD150 (csCD150) 
expression level on CLL B cells is associated with 
favourable prognosis for patients. However, the role 
of CD150 in the pathobiology of CLL is still unclear.
The aim of our study was to explore CD150 signal­
ling properties in CLL B cells.
Methods: flow cytometry, qPCR, Western blot 
analysis, in vitro stimulation assay, confocal micros­
copy. 
Results: We found that csCD150+ CLL B cells 
expressed CD180, CD95, CD20, CD22, CD48 and 
HLA­DR on significantly higher levels than csCD150­ 
CLL B cells. In csCD150+ CLL cases the basal level 
of tyrosine phosphorylation and phosphorylation 
of serine/threonine specific motifs that are substrates 
for AMPK, Akt, PKA, PKC, CDK kinases was higher 
compared to that in csCD150− CLL B cells. CD150 li­
gation on CLL B cells led to activation of pro­survival 
Akt, mTOR, ERK1/2, JNK1/2 and p38MAPK signal­
ling pathways. However, simultaneous crosslinking 
of CD150 and CD180, which showed the highest level 
of colocalisation on the cell surface of CLL B cells, dis­
played inhibitory effect on activation of Akt/mTOR sig­
nalling pathway, as well as MAPK pathways. It should 
be noted that profile of CD150 and CD180 expression 
is similar in majority types of B­cell leukemia and lym­
phoma, with highest expression level in CLL B cells. 
Moreover, our analysis of CD150 and CD180 expres­
sion on malignant B cell lines revealed coexpression 
of these receptors only in Burkitt lymphoma cell 
line BJAB. In contrast to CLL B cells, CD150 and 
CD180 on BJAB cell line were not involved in regulation 
of Akt, ERK1/2 or p38MAPK pathways.
Conclusions: CD150 and CD180 in case of their 
coexpression and coactivation could block propaga­
tion of pro­survival pathways in CLL B cells leading 
to disease attenuation.
CREATING GENETIC CONSTRUCTS 
FOR DETERMINING SPATIO-TEMPORAL 
DISTRIBUTION OF CORTACTIN AND THE 
PH DOMAIN OF BCR IN MAMMALIAN CELLS
D. Gurianov*, S. Antonenko, G. Telegeev
Institute of Molecular Biology and Genetics,  
NAS of Ukraine, Kyiv, Ukraine
*E-mail: dmitriy.gurianov@gmail.com
Background: Translocation between 9th and 22nd 
chromosomes leads to generation of a BCR-ABL fu­
160 Experimental Oncology 40, 154–176, 2018 (June)
sion gene. During the translocation, breakpoints are 
different in a BCR part and identical in an ABL part. 
As a result, generated chimeric proteins differ in pre­
sence or absence of certain domains of BCR. Previ­
ously, 23 potential interaction partners of a PH domain 
of BCR were identified by mass­spectrometry. They 
are involved in various important cellular functions, 
such as regulation of proliferation, signaling and cy­
toskeleton re­organization. These data, however, re­
quire further validation by more reliable methods. For 
our study, we selected cortactin (CTTN) as it is known 
to regulate actin branching and membrane remodel­
ing during clathrin­mediated endocytosis through 
interaction with dynamin that anchors to membrane 
by its own PH domain. Recently, we have discovered 
that CTTN, the PH domain and clathrin co­localize 
in specific regions of a cell, around the nucleus. This 
may indicate that the PH domain of BCR acts similarly 
to the PH domain of dynamin in clathrin­mediated 
endocytosis.
Aim: To further investigate this phenomenon, 
we decided to determine localization of these pro­
teins on a sub­diffraction level, using stimulated 
emission depletion (STED) microscopy. We also 
plan to determine their temporal distribution inside 
the cell by utilizing a fluorescent timing pheno­
menon. 
M e t h o d s :  To  a c c o m p l i s h  t h e s e  t a s k s , 
we amplified the DNA sequence, corresponding 
to a coding region of CTTN and the PH domain, 
by PCR. Obtained fragments were ligated to the 
pBluescript II SK+ vector. After verification of in­
serts they were sub­cloned to vectors, designed 
for super­resolution imaging and fluorescent tim­
ing. The PH domain of BCR was sub­cloned to the 
vector mEos3.2­C1 for fluorescent timing and 
photo­activation localization microscopy (PALM). 
CTTN was sub­cloned to the vectors pSlow­FT­N1, 
pMediumFT­N1 and pFast­FT­N1 for fluorescent 
timing. For STED imaging, the pEGFP­PH vector, 
previously created in our department, was used 
to transfect HEK293T cells to further investigate 
intracellular distribution of the PH domain of BCR 
on the sub­diffraction level.
Results: We have created and verified genetic 
constructs for the fluorescent timing of CTTN and the 
PH domain. We obtained super­resolution images 
of intracellular distribution of the PH domain of BCR 
on Leica TCS SP8 STED microscope.
Conclusions: Derived genetic constructs may 
be used for determining spatio­temporal distribution 
of the PH domain of BCR and cortactin. STED micros­
copy demonstrates that the PH domain of BCR clusters 
in structures that resemble clathrin­coated vesicles 
by size and shape, however, this hypothesis requires 
further validation by counter­staining of clathrin­
coated vesicles.
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TUMOR-ASSOCIATED ABNORMALITIES 
IN A MICRO-RNA EXPRESSION SIGNATURE 
CAN CONTRIBUTE TO THE DISRUPTION 
OF EPITHELIAL TISSUE INTEGRITY
V. Halytskiy*
Palladin Institute of Biochemistry, NAS of Ukraine, 
Kyiv, Ukraine
*E-mail: volha@biochem.kiev.ua
Background: Normal epithelial cells form a well­
ordered sheet where the cells are tightly bound to each 
other and to basement membrane and undergo con­
tact inhibition of proliferation and movement. On the 
contrary, impaired adhesion, detachment from the 
neighboring environment, anoikis resistance, epitheli­
al­mesenchymal transition (EMT), aberrant orientation 
of mitotic spindle, loss of apical­basal polarity and 
overcoming of contact inhibition are typical features 
of cancer cells, contributing to uncontrolled cell pro­
liferation and expansion.
The aim: As overexpression and downregulation 
of microRNAs (miRNAs) are necessary for cancer cells 
to grow and survive, this research aims to identify how 
the shifts in miRNA expression profile can promote the 
disruption of epithelial tissue integrity.
Methods: miRNA targets within gene transcripts 
were predicted in silico using the TargetScan software.
Results: Overexpressed miRNAs miR­18, miR­19, 
miR­21, miR­23, miR­27, miR­29, miR­155, miR­181, 
miR­210, miR­221/222 and miR­375 can silence 
genes that encode key molecules responsible for cell­
cell adhesion — E­cadherin (encoded by CDH1 gene), 
claudin 1 (CLDN1), junctional adhesion molecules 
JAM­A and JAM­C (F11R and JAM3), tight junction 
proteins ZO­1 and ZO­2 (TJP1/2), occludin (OCLN), 
cingulin (CGN), nectins 1 and 3 (PVRL1/3), nectin­
like molecules 1 and 2 (CADM3/1), alpha­catenin 
(CTNNA1), p120­catenin (CTNND1), alpha­actinins 
(ACTN1/2), tropomyosin 1 (TPM1) and vinculin (VCL). 
In addition, hyper­expressed miRNAs can suppress 
CRB1, MPP5 and INADL, DLGL1 and PARD3 genes 
encoding CRB1/PALS1/PATJ, DLG and PAR3 — main 
components of, respectively, CRB, SCRIB and PAR 
complexes responsible for the establishment of epi­
thelial cell polarity. Some overexpressed miRNAs can 
silence also genes involved in mitotic spindle orienta­
tion — VHL, APC, PROX1. Moreover, overexpressed 
miRNAs can affect the Hippo pathway by silenc­
ing of WWC1 (KIBRA), LATS2, STK3/4 (MST2/1), 
LATS1 and SAV1 genes. At the same time, down­
regulation of miR­15/16 and miR­205 allows hyper­
expression of YAP1 and, respectively, WWTR1 (TAZ) 
genes which transcripts carry targets of these miRNAs. 
The Hippo pathway failure allows entry of YAP1/TAZ 
transcription factors into the nucleus. In addition, 
hyper­expressed miRNAs can silence PTK2 (FAK), 
SPRY2, ARHGEF7 (PIXB) and PAK1 genes that en­
code components of the FAK/Src kinase pathway. 
Transcripts of SNAI1 (Snail), SNAI2 (Slug), ZEB1/2, 
TWIST1, KLF8, TCF4, SIX1, FOXC2 and LEF1 genes 
carry targets of downregulated miRNAs miR­15/16, 
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miR­22, miR­31, miR­34, miR­101, miR­124, miR­125, 
miR­137, miR­140, miR­143, miR­145, miR­148/152, 
miR­199, miR­200, miR­203, miR­204 and miR­205. 
Down­regulation of these miRNAs is characteristic 
to the cancer cells and allows reactivation and hyper­
expression of above genes encoding the key transcrip­
tion factors responsible for the EMT. Moreover, targets 
of down­regulated miRNAs are revealed in transcripts 
of VIM, FN1, CDH2 and CDH11 genes encoding me­
senchymal cell markers vimentin, fibronectin, N­ and 
OB­cadherin, expression of which is the sign of EMT.
Conclusions: Tumor­associated abnormalities 
in miRNA expression signature can contribute to loss 
of E­cadherin and silencing of many other epithelial 
junction and polarity genes as well as to de­repression 
of genes, responsible for the EMT, mesenchymal 
phenotype and stem­like properties. In addition, this 
leads to randomized mitotic spindle orientation and 
to symmetric division of cells, despite the normal 
asymmetric division. Silencing of Hippo cascade and 
FAK/Src pathway leads to attenuation and nullification 
of the contact inhibition signals as well as reduces 
or prevents their generation. As a result, transformed 
cells form irregular multi­layer conglomerates. These 
events disrupt the epithelial tissue integrity, facilitate 
cell detachment, proliferation, movement and in­
vasiveness, underlying the tumor progression and 
metastasis.
EVALUATING THE INFLUENCE 
OF MULTIPOTENT MESENCHYMAL STROMAL 
CELLS DERIVATES ON AN EARLY STAGE 
OF BREAST CANCER
T. Herheliuk1, 2, *, O. Perepelytsina1, 
L. Ostapchenko2, M. Sydorenko1
1Department of Biotechnical Problems 
of Diagnostics, Institute for Problems of Cryobiology 
and Cryomedicine, NAS of Ukraine, Kyiv, Ukraine
2Educational and Scientific Centre  
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Background: Tumor microenvironment plays 
a decisive role in cancer development and metastasis, 
and affects the therapeutic effectiveness of antican­
cer drugs. Multipotent mesenchymal stromal cells 
(MMSCs) are important elements of tumor stroma, 
but the effect of MMSCs on cancer cells development 
has not yet completely understood. MMSCs can both 
stimulate and inhibit tumor progression, depending 
on the components of microenvironment, genesis 
and stage of cell differentiation. Special attention 
is focused on the paracrine effect of products secreted 
by MMSCs.
The aim: Authors wanted to characterize the 
influence of derivates from human bone marrow 
MMSCs on proliferation, survival, receptor profile 
of MCF­7 in 2D and 3D cell cultures in vitro.
Methods: The monolayer MCF­7 cell culture was 
cultured in standard conditions (37 °C, 5% CO2, humi­
dity 95%), in DMEM nutrient medium (Sigma, USA), 
with 2 mM L­glutamine (Sigma, USA), 40 �g/ml Gen­
tamicin (Biopharma, Ukraine). The initial density of in­
oculated MCF­7 cells was 2 • 104 cells/cm2. Human 
bone marrow MMSCs were used in this work. To as­
sess the effect of MMSCs derivates on proliferative 
activi ty and adhesion properties of tumor popula­
tion, the MCF­7 cells were incubated in full nutrient 
conditioned media from MMSCs in 1:1 ratio. For the 
initial generation of spheroids the DMEM nutrient 
medium with 2% carboxymethyl cellulose (Bio­Rad, 
USA) was used. Plates with spheroids were being 
incubated on an orbital shaker PSU­10i, (Biosan, 
Latvia) at 80 rpm for 3–5 hours. The spheroid culture 
was maintained for 7 days. Cell viability was evaluated 
by MTT assay. The Stemi2000 software Axio Vision 
Red 4.7 (Zeiss, Germany) was used for processing 
the images. The volume of aggregates was calculated 
by Bjerkvig formula after 7 days of cultivation. Markers 
were detected by applying IHC method with primary 
monoclonal antibodies Ck (clone AE1/AE3, IS053, 
Dako, USA), vim (Clone V9, IS630, Dako, USA), EpCAM 
(Sigma, HPA026761, USA).
Results: The impact of MMSC derivatives 
on breast cancer cells in vitro and in vivo was esti­
mated. The significant cytostatic effect of the products 
of human bone marrow MMSCs on tumor population 
was detected.
Conclusions: MMSC derivates inhibited migration 
of tumor cells to suspension fraction and promoted 
an increase of expression of tumor associated mar­
kers — cytokeratins and EpCAM in 2D and 3D cell 
cultures, but only in 3D culture expression of vimentin 
was increased.
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IRE1 INHIBITION MODIFIES 
THE EXPRESSION OF TUMOR GROWTH 
RELATED GENES IN GLIOMA CELLS
O. Hnatiuk*, O. Luzina, D. Minchenko, 
I. Garmash, O. Minchenko
Palladin Institute of Biochemistry, NAS of Ukraine, 
Kyiv, Ukraine
*E-mail: oksana_mol@bigmir.net
Background: We have studied the effect of inhibi­
tion of the IRE1 signaling enzyme as well as hypoxia 
on the expression of genes, encoding important tu­
mor growth related proteins (BRCA1, DEK, BCL2L1, 
COL6A1, TPD52, HOMER3, and GNPDA1) in U87 gli­
oma cells. Therefore, hypoxia affected the expression 
level of numerous genes and the effect of low oxygen 
condition on most hypoxia responsive genes expres­
sion is dependent on IRE1 functional activity. Several 
genes have already been correlated with glioblastoma 
multiforme, but mechanisms of their regulation by hy­
poxia and IRE1 signaling pathway are not clarified yet.
The aim: We wanted to investigate the effect 
of hypoxia as well as IRE1 inhibition on the expression 
of BRCA1, DEK, BCL2L1, COL6A1, TPD52, HOMER3, 
and GNPDA1 genes in U87 glioma cells with hopes 
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of elucidating its mechanistic part in the development 
and progression of glioblastoma and the contribution 
to endoplasmic reticulum stress.
Methods: Exposure of glioma cells under condi­
tions of hypoxia, RNA isolation, reverse transcription 
and quantitative polymerase chain reaction in real 
time analysis.
Results: It was shown that the expression level 
of breast cancer 1 early onset (BRCA1) and tumor 
protein D52 (TPD52) mRNAs is strongly up­regulated 
in U87 glioma cells by inhibition of IRE1 in comparison 
with the control cells. At the same time, the expres­
sion level of collagen, type VI, alpha 1 (COL6A1), DEK 
oncogene (DEK), glucosamine­6­phosphate deami­
nase 1 (GNPDA1) and homer homolog 3 (HOMER3) 
is significantly down­regulated in glioma cells at this 
experimental condition. It was also shown that hy­
poxia up­regulated the expression level of COL6A1 and 
TPD52 mRNAs and down­regulated — BRCA1, DEK, 
and GNPDA1 mRNAs in control glioma cells and that 
inhibition of IRE1, which control cell proliferation and 
tumor growth, modifies the effect of hypoxia on the 
expression of COL6A1, DEK, BCL2L1, HOMER3, and 
GNPDA1 genes.
Conclusions: The present study demonstrates 
that hypoxia affects the expression of most studied 
genes in IRE1­dependent manner, but several aspects 
of this regulation warrant further investigation.
KNOCKDOWN OF THE ADAPTOR 
PROTEIN RUK/CIN85 IN 4T1 AND LLC 
ADENOCARCINOMA CELLS RESULTS 
IN INCREASED EXPRESSION LEVELS 
AND ACTIVITIES OF MMP-2 AND MMP-9, 
ASSOCIATED WITH ELEVATED PRODUCTION 
OF ANGIOSTATINS AND SUPRESSION 
OF INVASION POTENTIAL
I. Horak, T. Skaterna*, D. Gerashchenko, 
A. Tykhomyrov, O. Khudiakova, L. Drobot
Palladin Institute of Biochemistry, NAS of Ukraine, 
Kyiv, Ukraine
*E-mail: skaterna.t@ukr.net
Background: The degradation of extracellular 
matrix (ECM) by matrix metalloproteinases (MMPs), 
mainly by MMP­2 and MMP­9, has been consistently 
correlated with migration, invasion as well as angio­
genesis in many cancer subtypes including breast 
and lung cancer. However, an increasing number 
of publications are accumulated demonstrating that 
up­regulation of certain MMPs in tumor cells provides 
a beneficial and protective effect in the course of tumor 
progression while broad spectrum small molecular 
MMPs inhibitors proved to be ineffective in clinical 
trials. There is also evidence suggesting the role 
of MMP­2/MMP­9 in plasminogen digestion resulting 
in generation of angiostatins (kringle­containing frag­
ments of plasminogen) that could function as inhibitors 
of angiogenesis and tumor growth in different in vitro 
and in vivo experimental models. Interestingly, accord­
ing to our preliminary data, overexpression of adaptor 
protein Ruk/CIN85 in mouse breast adenocarcinoma 
4T1 cells resulted in the development of highly aggres­
sive phenotype associated with decreased expression 
of MMP­2 and MMP­9.
The aim: To study the interplay between Ruk/
CIN85 knockdown, MMPs expression, production 
of angiostatins and invasion potential of tumor cells 
using as the models of mouse breast adenocarcinoma 
4T1 cells and Lewis lung carcinoma (LLC) cells.
Methods: To down­regulate Ruk/CIN85, 4T1 and 
LLC cells were stably infected with lentivirus encoding 
Ruk/CIN85­specific shRNA. Protein expression levels 
were assessed by qRT­PCR and Western­blotting. 
Gelatin zymography was used to study enzymatic ac­
tivity of MMPs. Cancer cells invasiveness was studied 
using Boyden chamber assay.
Results: It was demonstrated that considerably 
increased expression levels and gelanolytic activities 
of both MMP­2 and MMP­9 were observed in condi­
tioned medium of Ruk/CIN85 knockdown 4T1 and LLC 
cells in comparison with control ones. Up­regulation 
of MMPs was shown to correlate with increased ge­
neration of angiostatins and suppression of invasion 
potential. MMPs inhibitor GM6001 at concentra­
tion 1.3 • 10­6 M restored the invasiveness of Ruk/
CIN85 knockdown cells to the values characteristic 
for corresponding control cells.
Conclusions: Based on our findings, it could 
be assumed that adaptor protein Ruk/CIN85 is a con­
centration­dependent regulatory component of sig­
naling networks responsible for the control of MMPs 
expression and thus angiostatins production and 
modulation of invasion.
Acknowledgments: This work was partially sup-
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CD150 AND CD180 ARE INVOLVED 
IN REGULATION OF PU.1 TRANSCRIPTION 
FACTOR EXPRESSION IN CHRONIC 
LYMPHOCYTIC LEUKEMIA CELLS
V. Huryn*, I. Gordiienko, L. Shlapatska, 
V. Kholodniuk, S. Sidorenko
Department of Molecular and Cellular Pathobiology, 
R.E. Kavetsky Institute of Experimental Pathology, 
Oncology and Radiobiology, NAS of Ukraine,  
Kyiv, Ukraine
*E-mail: imgordiienko@gmail.com
Background: Transcription factor (TF) PU.1 is an im­
portant regulator of normal B­cell development. How­
ever, PU.1 expression is deregulated in numerous 
of B­cell malignancies. Downregulation of PU.1 was 
found in CD38 and ZAP­70 positive chronic lympho­
cytic leukemia (CLL) cases. This fact leads to consider 
PU.1 expression as a surrogate prognostic marker 
of CLL outcome. The question rises whether it is pos­
sible to regulate PU.1 expression in malignant B cells? 
Cell surface receptors with signaling properties are 
among potential regulators of TF expression and 
activity.
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That is why the aim of our work was to explore 
the regulation of PU.1 expression via CD150 and 
CD180 cell surface receptors in CLL B cells.
Methods: flow cytometry, qRT­PCR, Western blot 
analysis, in vitro stimulation assay.
Results: Our results showed that all tested 
CLL cases were characterized by a lower level 
of PU.1 mRNA compared to normal B­cell sub­
populations (p ≤ 0.02). The PU.1 protein was 
heterogeneously expressed between CLL cases 
with significantly highest level in csCD150+ than 
in csCD150− CLL cases (p = 0.002). Moreover, ex­
pression level of PU.1 target gene CD20 was elevated 
in csCD150+ CLL B cells. Stimulation of CLL B cells 
via CD150 or CD180 receptors resulted in increasing 
PU.1 mRNA level in CLL B cells with an additive effect 
of CD150 and CD180 coligation.
Conclusions: CLL B cells are characterized 
by decreased PU.1 mRNA level compared to normal 
peripheral blood B cells. For the first time we found 
positive correlation between CD150 and PU.1 protein 
expression in CLL B cells. Both CD150 and CD180 re­
ceptors are involved in regulation of PU.1 mRNA that 
potentially may lead to transcriptional program modu­
lation in CLL B cells.
ANALYSIS OF PARP1 AND HISTONE 
MODIFICATIONS BY CHIP-SEQ MAY ALLOW 
TO PREDICT GENES TRANSCRIPTIONALLY 
CONTROLLED BY PARP1
M. Ionov, A. Robaszkiewicz*
Department of General Biophysics,  
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University of Lodz, Lodz, Poland
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Background: Although the primar y role 
of PARP1 in a cell is still ascribed to its DNA safeguard 
potential, the last two decades have shed the light 
on the control of gene transcription by this protein. 
The new methodological approaches and state of the 
art technologies, such as chromatin immunoprecipi­
tation followed by a new generation sequencing and 
bioinformatic analysis uncover the genome­wide 
association of PARP1 with the chromatin. The search 
for PARP1 distribution in the genome of human breast 
cancer cells revealed the relatively strong correlation 
between PARP1 and POLR2A responsible for gene 
transcription. Furthermore, PARP1 co­occured with 
an estrogen receptor (ER) that enhances ER­sensitive 
gene expression in a hormone­dependent manner. 
PARP1 was found at genomic regions characterized 
by acetylation of H3K27 and strongly correlated with 
histone acetyltransferase. This enzyme activated 
both gene enhancers as well as proximal and distal 
gene promoters. Among histone metylation, the 
H3K9me3 and H3K4me1 showed co­distrubution 
with PARP1.
The aim: to find out whether PARP1 appears 
to regulate gene transcription by acting within these 
regulatory regions, bearing in mind that gene enhan­
cers are simultaneously characterized by POLR2A 
occurrence, H3K4me1 and H3K27ac (the latter is most 
frequently inserted by EP300).
Methods: various bioinformatic softwares.
Results: The subsequent analysis aiming to esti­
mate the distance between particular modifications 
and proteins and a gene transcription start site re­
vealed that they all occurred in proximity or spanned 
the region, where transcription pre­initiation complex 
assembled.
Conclusions: Further analysis of chromatin in­
teraction (such as 3C) and PARP1 silencing, followed 
by RNA­Seq are required to confirm PARP1 contribu­
tion to defining expression of genes predicted with 
bioinformatic tools to be controlled by identified en­
hancers and promoters.
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PLATELETS ARE ABLE TO CONVERSION 
OF ENDOGENOUS PLASMINOGEN 
TO FRAGMENTS AND TO SORT THEM
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Background: Platelets play an important role 
in the process of tumor angiogenesis. The onset 
of tumor angiogenesis involves a net change in bal­
ance between angiogenesis stimulators and inhibi­
tors in favor of the former. Platelets are a rich source 
of proangiogenic factors. They also store and release 
angiogenesis inhibitors. Platelets express surface 
growth factor receptors, which may regulate the 
process of angiogenesis. Activated platelets serve 
as pro­coagulant surfaces amplifying the coagula­
tion reactions.
The elucidation of regulation of the platelet func­
tioning by plasminogen/plasmin system is one of the 
priority areas of our research. Plasminogen/plasmin 
molecule proteolysis in the organism leads to the for­
mation of kringle­containing fragments (К 1–3, К 1–4, 
К 5 etc.) — angiostatins, that exhibit an anti­angiogenic 
effect. It has been shown that angiostatins are involved 
in signaling mechanisms that underlie many normal 
and pathophysiological processes in the organism, 
such as cell migration, angiogenesis, metastasis, 
tissue remodeling, wound healing, axon germination, 
and others. Thus, the interaction of angiostatins with 
targets on the plasma membrane of endothelial cell 
(ATP synthase, integrin αVβ3, c­met receptor of HGF 
etc.) leads to suppression of proliferative activity 
of cells and their ability to move and migrate. For some 
time, it was believed that angiostatine is produced 
in the organism by some types of tumors, and indeed, 
an increase of their generation is observed in tumor 
growth. However, it has recently been established 
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that angiostatin is found in the organism and under 
normal conditions, thus, being involved in physiologi­
cal processes. To date, only a few types of cells that 
are capable of generating angiostatin in the norm are 
identified, including monocytes and macrophages.
The aim: To determine the role of platelets in an­
giogenesis.
Methods: Detection of angiostatins was carried 
out by western blotting assay, using polyclonal an­
tibodies monospecific to K 1–3 and K 5, which have 
been obtained by us for this purpose.
Results: We are investigating ability of platelets 
to generate plasminogen fragments — angiostatins, 
internalize and secrete formed angiostatins by native 
and activated platelets. We obtained preliminary data 
on the interaction of isolated K 1–3 and K 5 plasmino­
gen fragments (angiostatins) with the platelet surface. 
After previous incubation of platelets with K 1–3 and 
K 5, the fragments were detected in isolated plasma 
membranes and absent in cell lysates. The antibodies 
to K 1–3 revealed plasminogen and 51 kDa angio­
statin­like fragment on membranes and in lysates, 
whereas antibodies to K 5 revealed miniplasminogen 
on membranes, and a microplasminogen in the inner 
medium of the cells, indicating the ability of platelets 
to conversion of endogenous plasminogen and to sort­
ing plasminogen fragments.
Conclusions: Most probably, platelets can con­
vert endogenous plasminogen and sort plasminogen 
fragments.
EFFECT OF CANCER VACCINES 
ON MANIFESTATION OF PARANEOPLASTIC 
ANEMIA AND LEVELS OF ANGIOGENESIS-
ASSOCIATED CYTOKINES IN MICE 
WITH A TRANSPLANTED HIGH-ANGIOGENIC 
VARIANT OF LEWIS LUNG CANCINOMA
O. Karaman*, N. Fedosova, O. Fedorchuk, 
I. Voyeykova, A. Ivanchenko, H. Didenko, 
G. Solyanik
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Background: The correction of cancer­associated 
anemia (CAA), the formation of which is directly as­
sociated with an increased level of proangiogenic 
cytokines, is an important task of clinical oncology. 
It is known that CAA results in an unfavorable prog­
nosis, worsens the condition of patients and, in the 
case of hemoglobin < 90 g/l, is a direct contraindi­
cation to a special antitumor treatment. One of the 
experimental tumor models for the study of CAA 
is a highly angiogenic variant of the Lewis lung carci­
noma (LLC/R9), the growth of which is accompanied 
by the development of anemia, splenomegaly, and 
thymus involution. Previously, we have investigated 
the possibility of anemia correction in LLC/R9 mice 
using cancer vaccines (CVs) prepared on the basis 
of LLC/R9 cell antigens (CV­LLC/R9) or LLC cell anti­
gens (CV­LLC), as well as anti­tumor and immunologi­
cal effects of such CVs. It has been shown that both 
vaccines did not prevent the development of CAA and 
splenomegaly, and CV­LLC/R9 even exacerbated the 
manifestations of anemia. However, both vaccines in­
creased the survival of mice with transplanted LLC/R9. 
The administration of CV­LLC significantly reduced 
the number and volume of metastases, increased the 
cytotoxic activity of natural killer cells, and prevented 
the negative effect of the tumor on the specific cyto­
toxic activity of splenocytes and macrophages in the 
presence of autologous blood serum. It is known that 
the activation of immune cells is accompanied by the 
production of humoral factors, each of which can 
be involved in the processes of forming paraneoplastic 
syndrome.
The aim of the study was to investigate the ef­
fects of CVs prepared on the basis of antigens of high 
(LLC/R9) or low­angiogenic LLC strains on the level 
of proangiogenic (IL­10, IL­1, TNF­α) and antiangio­
genic (IFN­γ, IL­4) cytokines in mice with transplanted 
LLC/R9.
M e t h o d s :  T h e  s t u d y  w a s  c o n d u c t e d 
on male C57Bl/6 mice with transplanted LLC/R9 car­
cinoma. CV was prepared from LLC cells (CV­LLC) 
or LLC/R9 (CV­LLC/R9); as an adjuvant, a protein­
containing metabolite of B. subtilis B­7025 was used. 
The introduction of CV (4 subcutaneous injections) 
was initiated on the 12th day of tumor growth. At the 
33rd day after tumor transplantation, supernatants 
of splenocytes and blood serum of experimental ani­
mals were analyzed for IFN­γ, IL­1, TNF­α, IL­4, and 
IL­10 levels, using the BD Biosciences test system 
(USA). The statistical analysis was performed, us­
ing the descriptive statistics and the Student’s t­test 
(StatSoft STATISTICA 7.0).
Results: In LLC/R9 control mice, we observed 
a marked tendency to a decreased IL­10 serum 
level, compared to intact animals. Also, splenocytes 
of control mice were characterized by the significantly 
diminished IL­1 level (by 79%, p < 0.05) and a marked 
tendency to increased IL­4 production, compared 
to intact mice. The introduction of CV­LLC resulted 
in a significant increase in the serum TNF­α levels 
(which, due to the high variability of the index, was 
close to the trend), which could partially contribute 
to the anti­metastatic action of the vaccine. The use 
of the CV­LLC/R9 vaccine resulted in a statistically 
significant increase in serum IL­1 levels (by 501%, 
p < 0.05), compared to unvaccinated tumor­bearing 
mice. A high level of a proangiogenic cytokine IL­1 can 
lead to more severe anemia in LLC/R9 mice after 
vaccination with CV­LLC/R9. The level of production 
of investigated cytokines by splenocytes of vaccinated 
animals did not differ significantly from the corres­
ponding indices of control animals.
Conclusions: The use of CV­LLC at the background 
of LLC/R9 growth led to the formation of more balanced 
content of the examined cytokines in the blood serum 
of animals (in particular, the increase of TNF­α and the 
prevention of hyper­production of IL­1), which most 
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likely predetermined the preservation of functional ac­
tivity of cellular antitumor resistance effects, provided 
anti­metastatic action and lengthened the survival time 
of the animals. The administration of CV­LLC/R9 re­
sulted in the accumulation of pro­angiogenic cytokines 
(in particular, IL­1) in blood serum and decreased level 
of antiangiogenic cytokines (IFN­γ), leading to more 
severe tumor­associated anemia.
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FATTY-ACID COMPOSITION 
IN THE GUERIN’S CARCINOMA 
MITOCHONDRIAL FRACTION OF RATS UNDER 
CONDITIONS OF Ω-3 POLYUNSATURATED 
FATTY ACIDS ADMINISTRATION
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Background: Despite the progress in cancer 
therapy, conventional cytotoxic therapies lead to un­
satisfactory long­term survival, mainly related to the 
development of drug resistance in tumor cells and 
toxicity towards normal cells. The ω­3 polyunsaturated 
fatty acids (PUFAs), eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA), can exert anti­neoplas­
tic activity by inducing apoptotic cell death in cancer 
cells either alone or in combination with conventional 
therapies. The ω­3 PUFAs potentially increase the 
sensitivity of tumor cells to conventional therapies, 
possibly improving their efficacy, especially in case 
of cancer cells resistance to treatment. Moreover, 
in contrast to traditional therapies, ω­3 PUFAs appear 
to cause selective cytotoxicity towards cancer cells 
with little or no to xicity to the normal cells. The influ­
ence of ω­3 PUFAs supplementation on lipid profiles 
and metabolism of subcellular organelles such as the 
mitochondria remains poorly understood. Mitochon­
dria play key roles in activating apoptosis in mam­
malian cells. Mitochondrial cytochrome c (cyt c) has 
been found to have dual functions in controlling both 
cellular energy metabolism and apoptosis.
The aim of this study was to assess the modi­
fication of fatty acid profiles in the Guerin’s carci­
noma mitochondrial fraction of rats under conditions 
of ω­3 PUFAs administration.
Methods:  The animals were administered 
ω­3 PUFAs for 4 weeks prior to the carcinoma implan­
tation and then for the entire duration of tumor growth. 
Daily dose was 120 mg of ω­3 PUFAs per kg of body 
mass. The content of fatty acids in the mitochondrial 
fraction was determined by using HRGC 5300 gas 
chromatographer in glass column with Chromosorb 
W/HP sorbent in 10% Silar 5CP liquid phase.
Results: The results of the research show that in the 
Guerin’s carcinoma mitochondrial fraction of rats dur­
ing the intensive growth of the tumor (14 days, which 
corresponds to the logarithmic phase of tumor growth) 
the levels of ω­6 PUFAs were: 9.5% of arachidonic acid 
(AA), 7.3% of linoleic acid (LA), 1.8% of docosatetranoic 
acid (DTA). At the same time the levels of ω­3 PUFAs 
were: 4.4% of DHA, 0.1% of alpha­linolenic acids 
(ALA). The ω­3 PUFAs administration prior to and 
post­implantation of tumor leads to increased levels 
of AA (20%), DHA (5.5%) and EPA (1.7%) if compared 
to tumor­bearing rats that didn’t receive the lipophilic 
nutrients. The high level of AA in tumor mitochondrial 
fraction of rats may indicate a decrease in their me­
tabolism as a result of competition with ω­3 PUFAs 
for enzymes. The derivatives of ω­3 PUFAs induce 
apoptotic cell death in the Guerin’s carcinoma via acti­
vating mitochondrial apoptotic pathways. The change 
of ω­3/ω­6 has been found to be significant in mem­
brane structure and mitochondrial functioning. The 
ω­3 PUFAs supplementation before and after implanta­
tion of the Guerin’s carcinoma resulted in a decrease 
of cyt c level in mitochondrial fraction and in an increase 
of the cytosolic cyt c. Through interaction with apoptotic 
protease activating factors (Apaf), cyt c can initiate 
the activation cascade of caspases once it is released 
into the cytosol. The mechanism of such action of the 
lipophilic nutrients under investigation can be realized 
through oxygenated active metabolites of ω­3 PUFAs 
(epoxyeicosatetraenoic acid, epoxydocosapentaenoic 
acid, resolvin D1).
Conclusions: The obtained results indicate that 
the ratio of ω­6/ω­3 PUFAs plays an important role 
in the metabolism of PUFAs of the tumor and may 
be considered as a potential marker for prognosis 
of tumorigenesis. Therefore, DHA and EPA are poten­
tial anticancer agents that might be used for adjuvant 
therapy or combination therapy with conventional 
anti­cancer drugs for the treatment of some forms 
of cancer with minimal toxicity.
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Background: HLA (human leukocyte antigens) 
chromosomal region on short arm of chromosome 
6 encodes cell surface molecules of human Major His­
tocompatibility Complex (MHC) specialized to present 
antigenic peptides to the T­cell receptor on T cells. The 
HLA­genes are organized into 3 chromosome regions 
according to the functions of expressed antigens 
(class I–III). The major function of the HLA­antigens 
is to induce and regulate the immune responses. 
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Lymphocytes that express CD8 react with HLA class 
I antigens that activate the cytotoxic function, requiring 
them to be capable of recognizing an infected cell. HLA 
class III genes encode molecules acting in inflamma­
tion; they express complement components C2, C4, 
and factor B; TNF­alpha and lymphotoxin. It is known 
that the increased rate of somatic rearrangements 
in HLA genes is one of the possible mechanisms of im­
mune evasion in the development and progression 
of some types of cancers.
The aim of our study is to analyze the frequency 
and range of somatic deletions and duplications in the 
HLA locus in the ovarian tumors of affected patients.
Methods: The study of genomic rearrangements 
in the HLA region was performed using LOH analysis 
of 2 STR­markers located in HLA chromosome region: 
D6S2678 (class I) and D6S2925 (class III). The frag­
ment analysis of the STR­markers was carried out 
by electrophoretic separation of the PCR products 
in a polyacrylamide gel on an automatic laser analyzer.
Results: In 26.1% of the ovarian tumors (6 out 
of 23), partial deletions/duplications of the HLA 
class I chromosomal region were detected. In 40.1% 
of samples (9 out of 22), somatic rearrangements 
were detected in the chromosomal region of the HLA 
class III.
Conclusions: The LOH analysis using the 
D6S2678 (Class I) and D6S2925 (class III) STR mar­
kers allows us to determine the somatic rearrange­
ments of the HLA region in malignant ovarian tumors, 
which could be used to predict the immunotherapy 
effectiveness and treatment outcome in ovarian can­
cer patients.
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Background: Previously, we have shown that 
mesenchymal stem cells (MSCs) from a bone marrow 
and adipose tissue differ in expression of cytoplasmic, 
nuclear and membrane proteins. These parameters 
play a role in a proliferative activity, migration proper­
ties, and apoptosis level of MSCs during long­term 
cultivation. Hence, a question arises how MSCs iso­
lated from different primary materials affect functional 
state of the organs of the immune system.
The aim of the present work was to determine 
the effect of transplanted allogeneic MSCs of bone 
marrow and adipose tissue on the thymus and spleen 
of C57Bl/6 mice.
Methods: The studies were conducted 
on 2–3­months­old males of C57Bl/6 mice, weighing 
20–24 g. MSCs were isolated and cultivated in a ste­
rile laminar box with compliance to the requirements 
of asepsis and antiseptics. MSCs were cultured 
in a CO2 incubator at 37 °C and 5% CO2 in DMEM with 
10–15% of fetal bovine serum, 1% of antibiotic­anti­
mycotic solution (Sigma­Aldrich, USA). The following 
groups of animals were formed: group 1 — intact (con­
trol group); group 2 — animals, to whom 0.5 ml of 0.9% 
NaCl solution (placebo) were injected (into the caudal 
vein); group 3 — animals, to whom 104 of allogenic 
bone marrow MSCs (bmMSCs) in 0.5 ml of PBS were 
injected; group 4 — animals, to whom 104 of allogenic 
adipose derived MSCs (aMSCs) in 0.5 ml of PBS were 
injected. Indicators of the weight of peripheral lym­
phoid organs relative to the body weight (weight index), 
evaluation of cellularity of the thymus and spleen 
of animals were estimated at 7, 18 and 25 days after 
the administration of MSCs.
Results: The administered bmMSCs have a stimu­
lating effect on the proliferative activity of thymocytes 
in vivo, as indicated by an increase in thymic cellularity 
at 7 and 18 days of study, compared with the control 
and placebo by 79 and 32%, respectively. On the 
25th day after the administration of MSC, the content 
of lymphoid cells in the thymus was reduced, com­
pared to the 18th day, but was significantly higher, than 
in intact animals and after administration of 0.89% 
NaCl. A reliable (p < 0.05) positive correlation of thy­
mus cellularity with weight index was observed after 
administration of bmMSCs.
On the 7th day after administration of bmMSCs, 
cellularity of spleen was significantly higher — by 26%, 
compared with control animals and by 17%, compared 
to animals, which were administered with the placebo. 
On the day 18th, the spleen lymphoid cell content was 
also significantly higher than in groups 1 and 2, but 
was less than on the 7th day. On the 25th day the num­
ber of lymphoid cells in the spleen was significantly 
reduced (by 42%), compared with the control animals 
and by 32%, compared to the animals which were ad­
ministered with the placebo. The content of lymphoid 
cells in spleen on the 25th day correlates with the weight 
index of spleen, indicating its involution. The weight 
index of the spleen directly correlates with the content 
of the lymphoid cells.
After the administration of allogeneic aMSCs on the 
7th and 18th day, the content of lymphoid cells in the 
thymus increased significantly, compared with control 
animals and placebo — by 93 and 42%, respectively. 
On the 25th day the content of lymphoid cells in thymus 
also was higher: by 53 and 86%, respectively. A posi­
tive correlation between cellularity of thymus and its 
weight index was established along the entire length 
of observation after the administration of aMSCs. After 
Experimental Oncology 40, 154–176, 2018 (June) 167
the administration of aMSC, the content of lymphoid 
cells in the spleen exceeded significantly that in the 
spleen of intact animals. The number of lymphoid 
cells increased significantly by 33 and 24%, compared 
to intact animals and the placebo group on the 7th day. 
On the 18th day, the cellularity of spleen in the animals 
with administered aMSCs was significantly higher — 
by 18 and 14%, respectively. On the 25th day, the lym­
phoid cell count was higher by 7 and 15%. The weight 
index of the spleen increased significantly until the 18th 
day of the experiment. On the 25th day the weight index 
of spleen did not differ from that in experimental group 
of animals and placebo.
On the 18th day in group 3 the cellularity of thymus 
was significantly higher, compared to the group 4: 2.93 ± 
0.10 • 106/mg and 2.17 ± 0.16 • 106/mg (p < 0.05), 
respectively. On the 7th and 25th days, there was no dif­
ference in thymus cellularity. On the 18th day, the thymus 
weight index in the group 3 was higher, compared to the 
group 4: 0.22 ± 0.01 (p < 0.05) against 0.16 ± 0.02. 
On the 7th and 25th days, there was no reliable difference 
of thymus weight index between these groups of animals.
On the 7th and 18th days after administration 
of bmMSCs and aMSCs, the cellularity of spleen 
in groups 3 and 4 did not differ significantly. On the 
25th day after administration of bmMSCs, the cel­
lularity of spleen was significantly lower, compared 
to administration of aMSCs: 1.90 ± 0.17 • 106/mg and 
2.90 ± 0.06 • 106/mg (p < 0.05), respectively.
On the 7th and 18th days after administration of MSCs, 
the spleen weight index in group 3 was significantly 
lower, compared to animals of group 4 (the day 7: 
0.65 ± 0.02 and 0.79 ± 0.04 (p < 0.05), respectively; 
the day: 0.62 ± 0.02 and 0.79 ± 0.04 (p < 0.05), re­
spectively).
Conclusions: Transplantation of allogenic bone 
marrow and adipose derived MSCs stimulates immune 
cell in the thymus and spleen to proliferate, which 
is confirmed by increasing cellularity of these organs 
and their weight indices.
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Background: The virotherapy started to be used 
for complex treatment of cancer when the ability 
of some viruses to kill cancer cells had been discov­
ered. In particular, Newcastle disease virus (NDV) 
is used for complex treatment of cancer because the 
virus is cytotoxic for malignantly transformed cells and 
can stimulate production of some cytokines (IFN and 
TNF) with anti­tumor activity. This virus has a low­level 
pathogenicity for human organism and can cause 
mild flu­like symptoms, conjunctivitis, and laryngitis. 
According to the literature data cells have various 
sensitivity to the virus in vitro which depends on NDV 
strain and types of cells.
The aim: To study the influence of NDV on the can­
cer and normal cells and to compare the viability of the 
cancer and normal cells infected with NDV in vitro.
Methods: The study was performed on non­small­
cell lung cancer cells (A549 cell line), porcine embryo 
kidney cells (SPEV cell line) and NDV (4 • 106 PFU). 
Cell culture and virological methods have been used 
in this study.
Results: We revealed a higher sensitivity of malig­
nant A549 cells compared with normal cells of kidney 
SPEV. The death of more than 50% of cells was noted 
at 1/40 virus dilution in SPEV cells and 1/320 dilution 
in A549 cells. The cytotoxic effect of NDV on tested 
cells was evaluated in 24–72 h after their incubation 
with virus.
Conclusions: 1) NDV is more cytotoxic for cells 
of non­small­cell lung cancer than for normal kidney 
cells. 2) This results can become a base for further in­
vestigations of interaction between tumor and normal 
cells with NDV and for creating of alternative ways for 
cancer biotherapy.
IRE1-DEPENDENT EXPRESSION 
OF SPECIFIC TO IGFBP miRNA IN GLIOMA 
CELLS
Yu. Lahanovska*, O. Minchenko
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Background: We have studied the level of mi­
croRNA miR­7 and miR­182 expressions in U87 glioma 
cells when inositol requiring enzyme 1 (IRE1) are 
inhibited. MicroRNAs are small, single­stranded non­
coding RNA molecules approximately 22 nucleotides 
in length, which are involved in the post­transcriptional 
regulation of gene expression through interaction with 
the 3'UTR region of target mRNA and following degra­
dation of mRNA. Recent research detected an abnor­
mal expression of the miRNAs in glioma, which could 
be useful biomarkers.
Methods: We analyzed total RNA from U87 glioma 
cells transfected by empty vector pcDNA3.1 (control) 
and cells without IRE1 signaling enzyme function 
(transfected by dnIRE1). For quantification of micro 
RNA we used quantitative polymerase chain reaction 
in real time. Firstly, we add a poly(A) tail to the miRNA 
in total RNA sample using poly(A)­polymerase. Next, 
we reverse transcribe the polyadenylated miRNA 
to generate first­strand cDNA for quantitative poly­
merase chain reaction in real time using universal 
RT primer. For amplification of the miRNA hsa­
miR­7 and hsa­miR­182­5p we used forward primers 
specific for each miRNA and universal reverse primer.
Results: It was shown that the level of miR­7 ex­
pression in glioma cells without IRE1 signaling enzyme 
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function is strongly increased (+113%) compared 
to control glioma cells measured by quantitative 
polymerase chain reaction in real time. The level 
of miR­182­5p expression in cells without IRE1 signal­
ing enzyme function is increased by 38% compared 
to control glioma cells. Also we have analyzed data 
for IGF1, IGF2, IGFBP1, IGFBP2, IGFBP3 and have 
found that 3'UTR region of these mRNAs have specific 
binding sites for different microRNAs and that some 
from these mRNAs can specifically bind miR­7 and 
miR­182­5p. Thus, the changes in the expression 
level of miR­7 and miR­182­5p in glioma cells without 
IRE1 signaling enzyme function can possibly contri­
bute to the decreased proliferation rate of these glioma 
cells mediated via IGF/IGFBP system.
Conclusions: We detected the miRNA binding 
sites in 3'­region of IGF/IGFBP mRNA family. Using 
quantitative polymerase chain reaction in real time 
we have shown that the expression level of microRNA 
miR­7 and miR­182­5p is increased in cells without 
IRE1 signaling enzyme function compared to control 
glioma cells that possibly affects the activity of IGF/
IGFBP system.
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Background: Malignant tumors development and 
progression cause destruction of surrounding healthy 
tissues and in a case of solid tumors also a forma­
tion of necrotic masses. Such destructive processes 
induce a massive chronic inflammation. A growing 
body of epidemiological and clinical data supports the 
concept that chronic inflammation promotes tumor 
development and progression. As a major pro­inflam­
matory cytokine, tumor necrosis factor (TNF­α) is able 
to act as an endogenous tumor promoter to bridge 
inflammation and carcinogenesis (Wang et al., 2008). 
On the other hand, the negative interaction between 
pro­inflammatory signals and skeletogenic pathways 
(BMP and Wnt) which occurs at the sites of inflamma­
tion can lead to bone tumors development.
The aim: To evaluate anti­inflammatory activity 
of novel 4­thiazolidinone­based derivatives towards 
TNF­α­induced inflammatory processes during 
osteoblast differentiation in mouse mesenchymal 
precursor cells.
Methods: We performed in vitro evaluation 
of functional effect of multifunctional heterocyclic 
4­thiazolidinone derivatives (compounds Les­4368, 
Les­4370, Les­3882 and Les­3288) at different doses 
(1 μM, 0.3 μM and 0.1 μM) on TNF­α induced inhibition 
of bone formation by mouse mesenchymal precursor 
cells of C2C12. These cells were induced to differenti­
ate into osteoblasts by different BMPs. Western blot 
analysis was used to elucidate a mechanism of anti­
inflammatory effects.
Results: We found that treatment of C2C12 cells 
with TNFα completely inhibited the myoblast diffe­
rentiation, as well as strongly inhibited BMP­induced 
osteogenesis. Treatment of these cells with investi­
gated compounds allowed in case of Les­4368 and 
Les­3882 to rescue the osteogenic differentiation from 
negative effect of TNF­α, and even to convert it from 
inhibitor into potentiator of osteogenesis compared 
with control. Possible involvement of NF­κB modula­
tion as a key mechanism mediating anti­inflammatory 
effects was validated by immunoblot assays.
Conclusions: Novel 4­thiazolidinone derivatives, 
Les­4368 and Les­3882, rescue osteogenesis from 
negative control of inflammation. The best effect was 
shown by compound Les­3882 that stimulated osteo­
blast differentiation at low dose (0.1 μM), presumably 
via modulation of NF­κB pathway.
PREDICTING MODEL OF REGULATORY 
RELATIONSHIPS BETWEEN LONG  
NON-CODING RNAs BC200/XIST 
AND DISEASE-ASSOCIATED microRNAs
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Background: Long non­coding RNAs (lncRNAs) 
are defined as a class of important heterogeneous 
ncRNAs with the length more than 200 nucleotides. 
The recent study suggested that lncRNAs bc200 and 
XIST participate in development of several unisex tu­
mors via binding disease­specific microRNAs.
The aim of research is to predict and identify 
miR­lncRNA (XIST and bc200) interactions in several 
selected cancers — breast cancer, glioblastoma, neu­
roblastoma.
Methods: We used LncRNADisease, Lnc2Cancer, 
Diana Tools to analyze present expression data of ln­
cRNAs ANRIL and XIST for selected diseases in silico. 
We used HMDD v2.0 and Mir2Disease databases 
to find possible involvement of target microRNAs 
in various diseases.
Results: Using computational analysis of dis­
ease­associated microRNAs (Diana Tools), we pre­
dicted potential microRNAs for the sponge activ­
ity of bc200 (miR­15, ­125, ­30 families) and XIST 
(miR­30, ­15 families). Then, we used the HMDD 
v2.0 and Mir2Disease databases to find possible 
involvement of these microRNAs in various cancers.
Conclusions: The miR 15 family is predicted 
to bind to XIST and bc200 lncRNAs that can suggest 
the potential link between these lncRNA in various 
cancers. We create our prediction model of potential 
Experimental Oncology 40, 154–176, 2018 (June) 169
regulatory network of lncRNAs bc200 and XIST that 
gives an opportunity to see a more systematic picture 
of epigenetic regulation.
TUMOR MARKERS FROM LIQUID 
BIOPSIES. BENEFITS AND LIMITATIONS
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Background: The early diagnosis, prognosis 
of tumor development and choice of an appropriate 
target for cancer therapy are the most important top­
ics in a modern oncology research. The most common 
cases of tumor diagnosis are when tumor is already 
symptomatic and/or detectable by ultrasound or other 
physical methods, and such late time of the diagnosis 
does not contribute to an effective treatment. Inves­
tigating tumor features, using tissue biopsy, we study 
only a spatially and temporally limited sample, which 
cannot give the whole picture of tumor characteristics. 
Applying the approach of detection of tumor markers 
in biological fluids (liquid biopsies) can be a good 
solution for such problems. Nevertheless, a work with 
bio­fluids also has certain limitations.
The aim of our work was the detection of putative 
markers of prostate and bladder cancers in biologi­
cal fluids of patients and evaluation of their potential 
use in clinics, as diagnostic or prognostic markers for 
these cancers.
Methods: We collected samples of urine and 
blood from patients with prostate and bladder cancers. 
We isolated DNA by a standard phenol­chloroform 
method from whole urine with preliminary CTAB pre­
cipitation. We isolated RNA, using Trizol from whole 
urine (for non­coding RNAs detection) from patients 
with bladder cancer and cell sediment from urine and 
plasma of the patients with prostate cancer. For de­
tection of the aberrant DNA methylation, we provided 
bisulfite treatment of DNA, followed by PCR with pri­
mers to methylated and un­methylated templates and 
an agarose gel electrophoresis. We used Real­Time 
PCR for detection of mRNAs and lncRNAs, which can 
be potential markers of prostate and bladder tumors.
Results: We found that PTEN, NKX3.1 and RASSF 
were methylated in 71.4% of samples, and the most 
frequently methylated gene was PTEN (87.5%). For 
bladder cancer, NKX3.1 was methylated in 100% of all 
cases, the RASSF1A gene — in 35 out of 36 cases. 
The results of relative expression of AurA, AurB, AurC, 
BRAF, EGF and YWHAZ in samples from patients 
with prostate cancer demonstrated that differential 
expression of all 6 genes could be identified in both, 
urine and plasma. We observed positive correlation 
between expression of the AurC and BRAF genes 
(rs = 0.688, p = 0.01), the BRAF and EGF genes 
(rs = 0.719, p = 0.01) and the YWHAZ and AurC genes 
(rs = 0.591, p = 0.01). The results also demonstrated 
that the relatively high levels of lncRNAs PANDAR and 
BC200 can be identified in urine samples from people 
with bladder cancer.
Conclusions: Markers, based on detection 
of methylation of the tumor suppressor genes in bio­
fluids, can tell about even an early stage of carcinoge­
nesis. However, it is difficult to apply them for the choice 
of treatment. Expression of oncogenes is quantitative, 
but these quantities do not show the picture of their ex­
pression in tumor itself. However, if the high expression 
of the specific oncogene is observed, this information 
can be used for the diagnosis and selection of the target 
for therapy. It is important, that they can be identified 
in plasma, because for any other tumors, except uro­
logical the blood sample can be more useful, than urine 
(probably). In addition, finally, the specific markers, 
such as lncRNAs can be used as a tool for diagnosis 
and prognosis of tumor development.
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Background: Chronic lymphocytic leukemia (CLL) 
is the most common form of leukemia in Europe and 
USA (about 30%). Most if not all CLL cases, are pre­
ceded by the monoclonal B­cell (MBC) lymphocy­
tosis, which occurs in 5–10% of people over the age 
of 40 and progresses to CLL with a frequency of about 
1% per year. Cells of CLL, despite being non­prolife­
rating, express a set of cytokine receptors. Among the 
most important are receptors for IL2 and TGFB. In lym­
phoid cells, the active canonical TGFB pathway leads 
to apoptosis. IL2 is one of the main inducers of T­cell 
activation and differentiation.
The aim: We asked a question what is the status of the 
IL2 and TGFB pathways in CLL cells, with an aim to un­
cover the molecular details of appearance of these cells.
Objects and methods: peripheral blood samples 
of CLL patients, immunofluorescent analysis, western 
blotting, bioinformatics analysis of publicly available 
data bases on expression.
Results: We have shown that the TGFB­SMAD cano­
nical pathway is not active in CLL cells. SMAD­ responsive 
genes, such as BCL2L1 (BCL­XL), CCND2 (Cyclin D2) 
and MYC are down­regulated in CLL cells, compared with 
B­cells of peripheral blood of healthy donors. Also, the 
170 Experimental Oncology 40, 154–176, 2018 (June)
IL2­induced JAK­STAT5 pathway is largely inactivated 
in CLL cells. Despite elevated expression of STAT2 and 
STAT5 genes at the mRNA level, STAT5­responsive 
genes, such as BCL2L1 (BCL­XL), CCND2 (Cyclin D2), 
HIF1A, ID1, MCL1 and MYC are downregulated in CLL­
cells, compared to peripheral blood B­cells of healthy in­
dividuals. Moreover, we have found that SMAD2 is almost 
not expressed in CLL cells. No nuclear heterodimers 
of SMAD4 and SMAD3 (­2) were detected. Importantly, 
a phosphorylated from of the STAT5 protein was detect­
ed; however, no nuclear signal of this form was observed.
Conclusions: The TGFB­mediated signaling 
is not active in CLL cells, due to low (or absent) 
expression of SMAD4. The phosphorylation status 
of SMAD2 and ­3 should be further elucidated. The 
inactivation of the JAK­STAT5 pathway could be ex­
plained by the high levels of soluble IL2RA, as was 
reported earlier. Another possibility could be inhibition 
of STAT2 phosphorylation, leading to inability to form 
the active transcriptionally protein heterodimers. 
The phosphorylation status of STAT proteins in CLL 
cells should be further illuminated. Also, expression 
of proteins, regulating nuclear export/import should 
be studied.
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Background: Although the prognosis of metastatic 
liver disease has recently improved, it still remains 
a treatment challenge. The 4T1_luc2 is a highly tumori­
genic cell line, which can spontaneously metastasize 
from the primary tumor to multiple distant sites includ­
ing lymph nodes, liver, lung, brain, and bone. Thus 
could be used as a relevant tumor model including 
the general field of immunization studies in oncology 
as well as liver metastases in particular.
The aim: To characterize the burden of liver me­
tastases in immunized and naïve individuals using 
experimental model of breast carcinoma in mice.
Methods: Liver samples (n = 31) were analyzed 
from mice transplanted with 4T1luc2 adenocarcinoma 
cells expressing variant of HIV­1 FSU_A enzyme with 
and without drug resistance mutations. 23 mice were 
transplanted with 4T1luc2 expressing proteases (PR) 
(PR­DNA immunized 15, naïve 8), from which 7 PR_Ai, 
8 PR_A2mut and 8 PR_A3mut. Controls (n = 8) received 
parental 4T1luc2 adenocarcinoma cells. Metasta­
ses were diagnosed and evaluated in formalin­fixed, 
paraplast­embedded liver tissues. For each mouse, 
the area of tumor metastases was quantified in 25 high 
power (×400) microscope fields of haematoxylin­eosin­
stained slides by computer­assisted morphometry 
using specialized NIS­Elements software (Nikon, To­
kyo, Japan). IBM SPSSv23 was applied for statistical 
analysis, including descriptive assessment as detection 
of mean values and standard deviation (SD).
Results: Liver micrometastases were found in livers 
of 18/23 of 4T1luc2_PR implanted mice. PR immunized 
mice developed metastasis in 10/15 mice and naïve 
in 8/8 examined cases, as well as metastasis were found 
in all control mice. In 4T1luc2_PR_Ai group 165 metasta­
ses were found with mean size 636.08 μm2 (SD ± 519.15), 
from which 112 (21.6 metastases per mouse (SD ± 5.94; 
mean size 682.02 μm2 (SD ± 581)) in immunized and 
53 (23.5 metastases per mouse (SD ± 10.6) with 
mean size 538.99 μm2 (SD ± 339.51)) in naïve animals. 
In 4T1_luc2­PR_A2mut group 148 metastases were 
detected, with mean size 999.9 μm2 (SD ± 1408.66), 
128 (23.8 per mouse (SD ± 10.4) metastases with 
mean size 1029.15 μm2 (SD ± 1506.25) in immunized 
and 20 (9.5 metastases per mouse (SD ± 6.36) with 
mean size 812.64 μm2 (SD ± 380.52) in naïve mice. 
In 4Tluc_2_PR_A3mut 65 metastases (21.67 per mouse 
(SD ± 8.62) with mean size 843.87 μm2 (SD ± 877.19), 
from which none were found in immunized mice. In con­
trol mice 27 metastases (3.37 per mouse (SD ± 3.2) with 
mean size 699.35 μm2 (SD ± 280.52) were detected. 
Inflammatory infiltrates consisting of neutrophils and 
lymphocytes were found in all groups.
Conclusions: Number of metastases per mouse 
among HIV_DNA­immunized mice implanted with 
HIV­PR expressing tumors tend to be lower than among 
naïve animals, but higher compared to control group. 
Only DNA­immunization with PR_A3mut tend to protect 
against liver metastases as none were found in immu­
nized animals, compared to other groups. However, the 
morphology suggests complex tumor­host interaction. 
Furthermore, 4T1luc2_PR tumors tend to form larger 
metastases compared to control group.
METHYLTRANSFERASE ACTIVITY UNDER 
THE INFLUENCE OF INTERACTION 
“CORE” 2'-5'OLIGORIBOADENILATES 
AND THEIR DERIVATIVES
R. Nikolaiev*, Z. Tkachuk
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Background: Disturbance in the balance of methyla­
tion /demethylation of DNA, which in turn serves as a key 
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event in epigenetic deregulation in carcinogenesis, was 
studied. At the moment, a number of inhibitors of DNA­
methyltransferases are known, but their mutagenic and 
toxic effects are a significant disadvantage of these 
compounds. Natural and synthetic oligoadenylates, 
which can bind and affect the work of epigenetic regula­
tors and transcriptional proteins through interaction with 
regulatory domains, can be used as safe analogues.
The aim: Study of the influence of natural and 
synthetic oligonucleotides on the activity of model 
DNA­methyltransferase in silico and in vitro.
Methods: “HyperChem” — modeling the structure 
of oligonucleotides “AutodockVina” — molecular dock­
ing “Way2drug” — simulation of toxicity and expression 
of mRNA “String” — cluster analysis of hypothetical 
expression of mRNA gel electrophoresis.
Results: It is shown that the most effective binding 
of oligonucleotides to methyltransferase occurs with 
3 and 5 monomeric aptamer. Toxicity analysis showed 
that LD50 of oligoriboadenylates is in the range 
of 200–1500 mg/kg. The study of individual oligo­
nucleotides in the DIGEP program showed their ability 
to activate the antioxidant and immune system with the 
simultaneous inhibition of methyltransferase activity. 
The electrophoretic distribution showed the ability 
of oligonucleotides to inhibit the methyltransferase 
reaction in a wide range of micromolar concentrations.
Conclusions: Thus, the analysis of molecular 
docking suggests that the oligoriboadenylates pos­
sess the highest energy of binding with the model 
DNA­methyltransferase EcoRI.
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Background: Among the current problems of clini­
cal oncology (screening, prevention, early diagnosis, 
personalized treatment), one of the topical issues — 
the individual risk of malignant neoplasms — is of par­
ticular interest, although for most of them, including 
cancer of the female reproductive organs (FRO), risk 
factors are mostly already defined [1–4].
The aim: To develop a prognostic molecular 
genetic model for assessing the risk of development 
of benign and malignant tumors of FRO in patients 
from cancer­affected families.
Methods: The work presents the data on a compre­
hensive clinical examination of 210 women (90 patients 
with FRO cancer with aggregation of tumor pathology 
in families, 65 patients with benign pathology of FRO 
from cancer­affected families, 55 women — control 
group of healthy women without family history of can­
cer). Clinical genealogical analysis, morphological 
examination of tumors and molecular genetic studies 
of genomic DNA from peripheral blood and tumors 
was carried out.
Results: It was established that in the families 
of patients with benign and malignant pathology 
of FRO, malignant tumors associated with Lynch II syn­
drome are observed. Based on the analysis of detected 
ESR­1, Cyp2D6*4 and mutations in BRCA1/2 genes 
in cancer patients and in patients with benign patho­
logy, molecular genetic models have been developed 
to assess the individual risk of development of benign 
and malignant tumors of FRO. It has been established 
that these molecular genetic models and combinations 
of gene mutations and gene polymorphisms (SNP) 
by the intergene interaction that was analyzed, were 
found to be reliable in assessing the risk of benign and 
malignant pathology of the mammary gland and ovary.
Conclusions: The model, which included the poly­
morphic variants of the T397ESR1/Cyp2D6*4 genes 
was of the best predictive accuracy for the evaluation 
of the risk of benign tumors of the FRO (71.68%) and 
the highest reliability (p < 0.001). At the same time, 
all identified models of intergene interaction in the 
development of malignant pathology of FRO were 
reliable, prognostically significant with high reproduc­
tion and almost identical accuracy (65.00–68.23%). 
The obtained results indicate a high informativeness 
of such molecular genetic indices as the polymor­
phism of ESR1 and Cyp2D6*4 genes and mutations 
in BRCA1/2 genes to assess the risk of benign or ma­
lignant tumors of FRO in families of patients with family 
history of cancer.
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COMPETITIVE INHIBITION — NEW 
PERSPECTIVE ON Klebsiella spp. 
AS A TRIGGER OF CARCINOMATOSIS
V. Petrishchak*, O. Karbovanets, G. Koval
Department of Microbiology, Virology, Epidemiology 
with the course of infectious diseases,  
Uzhhorod National University, Uzhhorod, Ukraine
*E-mail: lachupakabramail@gmail.com
Background: Klebsiella is referred to endemic 
diseases of Western regions of Ukraine, including 
Transcarpathia. Despite the frequent isolation of their 
pathogens from the nasal microbiome (especially the 
Klebsiella pneumoniae strain), the role of the carcino­
genesis trigger remains uncertain.
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The aim: Research of antagonistic and inhibitory 
properties of a non­pathogenic strain to prevent the 
occurrence of cancer conditions.
Methods and results: After a bacteriological 
study of 47 patients with a diagnosis of oropharyn­
geal cancer, laryngeal cancer, oral cancer, cancer 
of the tongue root, larynx cancer with rhinophyma, 
5 strains of Klebsiella rhinoscleromatis and 2 strains 
of Klebsiella ozaenae, 3 — K. pneumoniae were iso­
lated. Numerous studies describe the mechanism 
of “avoidance” of the immune response by bacteria, 
which persist in tumors of the gastrointestinal tract 
and uterus, since the tumor is intact and has an im­
perfect system of blood supply. It is known that these 
species lead to chronic inflammation, atrophic or hy­
perplastic changes in the epithelium. So can they lead 
to malignancy in people with a genetic predisposition 
or against a background of precancerous conditions?
We also evaluated the functional activity of fol­
licular, epithelial dendritic cells and peripheral blood 
cells in response to contact with Commensal, as well 
as a we made comparative analysis of the cytokine 
profile of K. pneumoniae S (wild, pathogenic strain), 
R (the mutant strain was obtained by culturing 
in the presence of crystals with nitrosoguanidine) 
and B. subtilis 090 in vitro. We found weak im­
munosuppressive activity in the pathogenic strain, 
moderate synthesis of IL­6 bacilli, and sufficient syn­
thesis of pro­inflammatory IL­10, ­12 and TNF­α non­
pathogenic strain.
The antagonistic properties of the mutant strain 
were also evaluated by prolonged cultivation with 
pathogenic strain. Expressive suppression of the viru­
lent strain was observed after 48 h in vitro.
Conclusions: Since the mutant strain is not patho­
genic and has the ability to initiate a systemic immune 
response rather than a local one, it can be further 
recommended as a promising anti­Klebsiella vaccine 
preparation. And one of the directions of targeted 
therapy is expedient to consider the introduction into 
the body of noncapsular mutant strains of K. pneu-
moniae S for competitive inhibition of pathogenic 
strains, increasing the activity of dendritic cells and 
combating resistance to antitumor drugs.
PARP-1 INHIBITORS MODULATE CYTOKINE 
TRANSCRIPTION IN A THP-1 MODEL 
OF ACUTE MONOCYTIC LEUKEMIA
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Background: Acute monocytic leukemia (AML) 
belongs to a malignant bone marrow neoplasm, as­
sociated with hyperleukocytosis and coagulation 
abnormalities. The most frequently encountered 
form is observed in young children under 2 years 
old. In AML, more than 80% of leukemic cells belong 
to monocyte lineages such as promonocytes and 
monocytes. THP­1 cells represent the immortalized 
monocyte­like cells and are derived from a 1­year 
infant with AML. These cells resemble healthy mono­
cytes, but maintain capacity to proliferate. THP­1 cells, 
similarly to immune response cells, produce a variety 
of pro­inflammatory cytokines. In AML a strong re­
sponse is an undesirable effect, nonetheless, during 
the cell contact with the high dose of bacterial endo­
toxin — lipopolysaccharide (LPS) the process of immu­
notolerance occurs. That phenomenon is associated 
with cell inability to produce cytokines (e.g. TNF­α) 
that in consequence impairs the functioning of im­
mune system. There are much data that show the role 
of PARP1 protein in many intracellular processes even 
in regulation of gene expression, which is engaged 
in pro­inflammatory response.
The aim: To confirm the first obtained data sug­
gested that the presence of PARP1 on the chromatin 
is involved in inhibition of immune tolerance.
Methods: The process of immune tolerance 
in THP­1 cells was induced with the high dose 
of LPS. To observe the role of PARP­1 in blocking 
of immunotolerance, cells were preincubated with the 
inhibitor of PARP­1 — Olaparib — which is responsible 
for PARP1 maintaining on the chromatin.
Results: The first data showed that in presence 
of PARP1 inhibitor the process of immune tolerance did 
not occur. Moreover, after differentiation of THP­1 cells 
with PMA (phorbol ester), the presence of inhibitor 
did not prevent the development of immunotolerance 
process. Those results suggested differences in the 
PARP­1 contribution to immunotolerance induction 
in differentiated and undifferentiated cells. Inhibitors 
of PARP­1, which are tested and utilized in cancer 
therapy, can stop the process of immunotolerance 
in AML.
Conclusions: In case of AML, the PARP­1 inhibi­
tors can stop the process of immunotolerance. Even 
if this is an undesirable process, nevertheless, the 
indication of basis of this process can be useful in im­
munotolerance prevention in healthy monocytes and/
or macrophages.
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CANCER ENZYMOTHERAPY: 
RIBONUCLEASES IN CANCER TREATMENT
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Background: Ribonucleases (RNase) catalyse 
the breakdown of RNA into smaller components. The 
cytotoxic effects of RNase include the RNA cleavage 
leading to the inhibition of the protein synthesis and the 
induction of apoptosis. In some cases, they become 
a source of micro­RNA. Attractive idea is to provide 
enzymes that selectively deplete certain types of RNA 
in tumor cells.
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There are two types of RNases — endoribonucle­
ases and exoribonucleases. Endoribonucleases are 
RNase A, RNase P, RNase H, RNase III, RNase T1, 
RNase T2, RNase U2, RNase V1, RNase I, RNase, 
PhyM and RNase V. Exoribonucleases include Poly­
nucleotide Phosphorylase (PNPase), RNase PH, 
RNase II, RNase R, RNase D, RNase T, oligoribonucle­
ase, exoribonuclease I and exoribonuclease II. Dif­
ferent RNases such as onconases, bovine seminal 
RNase, RNase T1, Sarcin, RNase P, actibind and 
RNaseT2 have recently been studied for the treatment 
of different type of cancers. Ribonucleoside 3'­phos­
phate could serve as a pro­moiety in Ribonuclease­
Activated Cancer Prodrug because it increases the 
hydrophilicity of a cancer therapeutic agent. RNases 
uniquely influence several functions in the tumor cell 
simultaneously and demonstrated the ability to over­
come multidrug resistance and to enhance the cy­
totoxicity of a variety of anticancer agents. Bovine 
seminal RNase (BS­RNase) is a unique member of the 
RNase A family which exist as dimer of RNase A like 
subunits which are linked by the disulfide like bridges. 
Dimeric form is able to evade ribonuclease inhibitor 
but not the monomeric form. Onconases were found 
to induce the caspase­9 — caspase­3 cascade, which 
is correlated with the release of cytochrome C from 
the mitochondria. The use of a novel approach based 
on the catalytic RNA subunit of RNase P can act 
as sequence­specific endonucleases and can exclu­
sively cleave target RNA that forms a base pair with the 
guide sequence (GS) to destroy RNA specifically the 
tumor­specific fusion genes. The sources of bioactive 
RNases may be of different origin. We hope that this 
advancement provides a new therapeutic tool for the 
treatment of cancer and holds some promise for more 
selective, non­toxic cancer therapy in the future.
Conclusions: This therapy promises to be an ef­
fective strategy for the treatment of the cancer.
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Background: Chronic myelogenous leukemia 
(CML) is a clonal hematopoietic stem cell disorder as­
sociated with the activity of BCR-ABL fusion oncogene. 
The molecular events underlying the transition from the 
chronic phase to the blast crisis are still poorly under­
stood. The transcription factor C/EBP­alpha (CCAAT/
enhancer­binding protein α) implicated as an inhibitor 
of cell proliferation and a regulator of differentiation 
plays a critical role in granulocytic differentiation. The 
progression of CML to blast crisis is correlated with 
down­modulation of C/EBP­alpha. Tavor et al. (2003) 
first shown that the restoration of C/EBP­alpha expres­
sion in BCR­ABL­positive KCL22 blast cell line trans­
fected with C/EBPα plasmide vector (pMTα) triggered 
a proliferative arrest, a block in the G2/M phase of the 
cell cycle and a gradual increase in apoptosis. There­
fore, C/EBP­alpha may be considered as a putative 
target in differentiation therapies in myeloid leukemias.
The aim of the study was to assess the potential 
of vitamin E as the possible inducer of C/EBP­alpha 
expression in BCR­ABL­positive CML K562 cells.
Methods: Total RNA was extracted using TRIzol 
(Invitrogen, Gaithersburg, MD) according to the manu­
facturer’s instructions. RNA was converted to cDNA 
using the Qiagen’s QuantiTect Rev. Transcription Kit 
(Qiagen, Hilden, Germany). C/EBP­alpha and G­CSFR 
mRNA expression was quantified by real­time RT­PCR 
using SYBR Green protocol. RT­PCR reactions were 
carried out using HotStarTaq DNA polymerase (Qiagen), 
50 ng of cDNA and SYBR Green in a 1:60,000 dilution 
in triplicate. PCR conditions were: a 95 °C initial activa­
tion for 15 min was followed by 45 cycles of 95 °C for 
15 s, 60 °C for 15 s, and 72 °C for 30 s on an Bio­Rad 
Real­time PCR Detection System IQ5, CA.
Results: We have not found detectable expression 
of C/EBP­alpha in K562 cells. Upon 48­h culture with 
vitamin E at a dose of 100 μM, K562 cells expressed 
both C/EBP­alpha and G­CSFR (granulocyte colony­
stimulating factor receptor).
Conclusion: Vitamin E restored the expression 
of C/EBP­alpha mRNA in CML K562 cells. In this 
setting, G­CSFR expression in vitamin E treated 
K562 cells seems to point out to the activation 
of at least one component relevant to granulocytic dif­
ferentiation. It should be further elucidated whether 
such effects of vitamin E on C/EBP­alpha transcrip­
tion factor are direct or mediated via antioxidant 
properties of vitamin E.
THE EFFECTS OF IMMUNIZATION 
WITH XENOGENEIC EMBRYO PROTEINS 
AFTER LEWIS LUNG CARCINOMA SURGICAL 
REMOVAL
T. Symchych*, N. Fedosova, O. Karaman, 
I. Voyeykova, G. Didenko
R.E. Kavetsky Institute of Experimental Pathology, 
Oncology and Radiobiology, NAS of Ukraine, Kyiv, 
Ukraine
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Background: Xenogeneic cancer vaccines utilize 
xenogeneic homologous proteins or genes as immu­
nogens to break immune tolerance towards tumor­
associated antigens. Homologous immunogens can 
be derived from a broad number of different species. 
R.E. Kavetsky Institute is conducting research on elab­
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oration of a xenogeneic vaccine based on chicken em­
bryo proteins (CEP). In the preliminary experiments, 
immunization with CEP after surgery prevented a Lewis 
lung carcinoma (LLC) metastases spread.
The aim of this research was to examine the effects 
of CEP on immune reaction of mice immunized after 
LLC surgical resection.
Methods: LLC cells (2.5 • 105 cells/mouse) were 
injected into a hind pad. The tumor was removed 
on day 17 after LLC cells transplantation. Thereafter, 
immunization was performed on day 1, 8 and 15. The 
cytotoxic activity (CTA) of immune cells was deter­
mined by the МТТ assay. Lymphocytes proliferation 
was studied by in vitro blast­transformation assay 
(LBTA). IL­4, IFN­γ, IgG level in blood serum was 
analyzed by ELIZA.
Results: Since day 21 until day 38 after the tumor 
resection, metastases were detected in 6/10 control 
mice and in 0/11 immunized mice. On day 7 and 
14 after tumor resection, the control mice showed 
features of surgically induced immunosuppression, 
namely decrease in NK CTA (by 2 and 2.5 times, 
0.05 < р < 0.1 and р < 0.05, respectively com­
pared to the intact mice), and increase in IL­4 level 
(by 1.6 and 1.8 times compared to the intact mice 
on day 7 and 14, respectively). On the contrary, in the 
immunized group NK CTA suppression was seen only 
on day 14; IL­4 production did not differ from the in­
tact mice. Moreover, in this group spontaneous LBTA 
significantly increased on day 7. The level of IFN­γ and 
IgG in the immunized group did not differ from the in­
tact mice, while increase in these indices in the control 
group correlated tightly with volume of metastases.
Conclusions: Overall, it is shown that protec­
tion from surgically imposed immune suppression 
may underlie CEP anti­metastatic activity. Further 
elaboration of xenogeneic CEP­based cancer vaccine 
is warranted.
IN SILICO STUDY OF THE CYTOKINE 
WITH ANTITUMOR ACTIVITY AIMP1/
P43 POSSIBLE INTERACTION WITH A NOVEL 
MOLECULAR PARTNER
O. Tsuvariev1, 3, *, I. Shuba2, V. Lylo1, I. Karpova1, 
O. Kornelyuk1
1Institute of Molecular Biology and Genetics, 
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Background: Multifunctional protein 1 (AIMP1/
p43) is an auxiliary component of higher eukaryote 
aminoacyl­tRNA synthetase complex (MARS). Being 
outside of the complex it demonstrates noncanonical 
pleiotropic cytokine activities: modulates the prolifera­
tion of different types of cells, stimulates apoptosis and 
inflammation, suppresses angiogenesis and growth 
of tumors [1]. Recently it was shown that the AIMP1/
p43 protein enhanced mediated immune responses via 
the up­regulation of Toll­like receptor 2 (TLR2) expres­
sion in mouse dendritic cells. These results indicate 
that AIMP1/p43 may enhance the immune responses 
by regulating the TLR2 expression [2]. It is known 
that TLRs not only play an important role in immune 
responses but recognize molecular partners, which 
are associated with cancer as well.
The aim: To reveal possible features of structural 
topography of these proteins underlying their interac­
tion.
Methods: Bacterial expression of AIMP1/p43, 
fluorescence spectroscopy, in silico search of AIMP1/
p43’s molecular partners, prediction and analysis 
of coiled coils and natively disordered regions with use 
of BioGRID 3.4, PRABI and PrDos bioinformatical tools.
Results: Our research has shown the key role 
of disordered and coiled regions in the formation 
of interaction interfaces of both molecules under 
study. Additional hydrophobic regions exposed on the 
AIMP1/p43 protein surface as a consequence of con­
formational changes might contribute to the multiple 
functional activity of the AIMP1/p43 protein.
Conclusions: Features of AIMP1/p43 structural 
organization may be essential for the binding with the 
TLR2 partner molecule during recognition process.
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IRE1 INHIBITION LEADS 
TO A TRANSCRIPTIONAL RE-PROGRAMMING 
OF U87 GLIOMA CELLS
D. Tsymbal*, O. Minchenko
Palladin Institute of Biochemistry, NAS of Ukraine, 
Kyiv, Ukraine
*E-mail: dariiabova@gmail.com
Background: Inhibition of a key sensory­signaling 
enzyme of the unfolded protein response pathway 
IRE1 (inositol­requiring signaling 1) leads to significant 
down­regulation of glioma growth. Understanding 
the mechanisms of this phenomenon is crucial for 
further research on glioma treatment strategies. In the 
department of molecular biology of Palladin Institute 
of Biochemistry of the National Academy of Sciences 
of Ukraine we accumulated a substantial amount 
of data on the differential gene expression in U87 gli­
oma cells upon inhibition of IRE1 signaling enzyme.
The aim: To perform a data meta­analysis.
Methods: Gene ontology analysis using PANTHER 
classification system (http://pantherdb.org/) [1]. 
Results: The expression of total 185 genes was 
studied in U87 glioma cells with IRE1 dominant­nega­
tive knockdown. The expression levels of 14 genes 
(7.5%) remained unchanged as compared to control 
U87 glioma cells with functional IRE1, whereas the rest 
of 171 genes (92.5%) were differentially expressed. 
The mRNA levels of 85 (46%) genes were changed 
more than 2­fold (either up­ or down­regulated) 
in IRE1­deficient glioma cells as compared to con­
trol. 20 genes exhibited more than a 5­fold change 
in their relative mRNA levels in IRE1­deficient glioma 
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cells. On the generated data sets (N1 = 185, N2 = 85, 
N3 = 20) we performed a PANTHER Overrepresenta­
tion test using default settings. Selected results were 
as following:
GO:0009966 — regulation of signal transduction: 
N1 — 88 genes (47.6%), N2 — 39 (45.9%), N3 — 
12 (60.0%);
GO:0042127 — regulation of cell proliferation: 
N1 — 68 (36.8%), N2 — 37 (43.5%), N3 — 11 (55.0%);
GO:0010628 — positive regulation of gene ex­
pression: N1 — 56 (30.3%), N2 — 27 (31.8%), N3 — 
9 (45.0%);
GO:0030154 — cell  dif ferentiation: N1 — 
64 (34.6%), N2 — 34 (40.0%), N3 — 13 (65.0%).
(Note: one gene can belong to different groups 
at once).
Conclusions: Inhibition of IRE1 signaling enzyme 
in U87 glioma cells leads to profound changes in the 
transcription of numerous groups of genes, to genome 
reprogramming. Our analysis has shown that the most 
prominent changes are characteristic for the genes 
implicated in such processes as cell differentiation, 
regulation of signal transduction, cell proliferation and 
gene expression.
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DOES LYS-PLASMINOGEN MAKE PLATELETS 
ANTI-ANGIOGENIC?
A. Tykhomyrov*, D. Zhernosekov, V. Korsa, 
T. Grinenko
Palladin Institute of Biochemistry, NAS of Ukraine, 
Kyiv, Ukraine
*E-mail: artem_tykhomyrov@ukr.net
Background: Angiogenesis is a key process 
to promote cancer, and anti­angiogenic treatment 
represents an established therapeutic strategy of can­
cer. Malignant cells (breast cancer, glioblastoma 
multiforme, and others) have been shown to recruit 
and stimulate platelets resulting in release of platelet­
stored growth factors, which activate angiogenesis 
and support tumor development. The endogenous 
angiogenic inhibitors, angiostatins (AS), which are 
derived by limited proteolysis of plasminogen (PG), 
reduce both angiogenesis and vascular permeability. 
Truncated PG form, Lys­PG, has been recently shown 
to inhibit platelet responses to agonists.
The aim: This study was designed to clarify 
if PG can affect platelet degranulation and secretion 
of vascular endothelial growth factor (VEGF), as well 
as participate in generation of AS by PG fragmentation.
Methods: Washed platelets were obtained from 
fresh human plasma by gel­filtration on Sepha­
rose­2B. Flow cytometry was used for the assess­
ment of Lys­PG (1.2 μM final concentration) effects 
on agonist­induced P­selectin as an alpha­granule 
secretion marker and surface actin exposition. PG was 
conjugated with a fluorophore probe, FITC, to study 
PG binding with platelet membrane. Secreted VEGF 
and PG cleaved products (AS­like polypeptides) were 
detected by western blot.
Results: Cytometry analysis indicates that 
Lys­Pg is able to inhibit agonist­induced alpha­granule 
release and P­selectin exposition on the platelet 
membrane. Lack of exposed P­selectin is known 
to destabilize platelet aggregates and contributes 
to reduced platelet rolling on endotheliocytes. Inter­
fered platelet secretion is also confirmed by the results 
of western blot demonstrating that Lys­PG­pretreated 
platelets became less sensitive to agonist action and 
released few amounts of angiogenic molecule, VEGF, 
compared to untreated cells. Platelets stimulated 
by thrombin or collagen were shown to expose in­
creased levels of cytoskeletal protein, actin, on their 
surface. Results of the binding assay demonstrated 
that surface­ exposed actin is involved in PG interaction 
with platelets. Incubation of platelets with either Glu­ 
or Lys­PG resulted in generation of cleaved products, 
angiogenic inhibitors AS. Anti­actin antibodies partially 
blocked binding of PG with platelets and prevented its 
further proteolysis. It can be assumed that plasmin, 
which can be converted from Lys­PG on the platelet 
surface, is responsible for the loss of platelet sensitivity 
to the agonist stimuli by receptor’s desensitization and 
is the key proteinase to provide AS formation.
Conclusions: Collectively, our data demonstrate 
for the first time that Lys­PG displays anti­platelet 
activities and restricts pro­angiogenic potential 
of platelets by inhibiting VEGF release and enhanc­
ing AS generation. With respect to involvement 
of platelets in tumor­induced angiogenesis, effects 
of Lys­PG platelet targeting may open new challenges 
to optimizing anti­angiogenic therapy of cancer.
STUDY ON LECTINS FROM THE ALBUMEN 
GLAND AND MUCUS OF Helix pomatia 
AS BUILDING BLOCKS FOR A PUTATIVE 
TEST-SYSTEM TO PREDICT IMMUNE 
RESPONSE UPON TUMOR GROWTH
V. Velykyi*, O. Garashchenko, 
O. Dvorshchenko, O. Kruts, G. Didenko
R.E. Kavetsky Institute of Experimental Pathology, 
Oncology аnd Radiobiology, NAS of Ukraine, Kyiv, 
Ukraine
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Background: Lectins represent a big group of pro­
teins and glycoproteins, which are capable to bind 
selectively glycans and glycan determinants on bio­
polymers. Almost all groups of organisms contain lec­
tins in different organs and tissues [1], and have a high 
potential for cancer diagnostic and therapy [2]. Diffe­
rent types of lectins are used as markers for screen­
ing of tumor process, as the therapy for oncological 
pathology [3], and for development of the anticancer 
vaccines [4]. For example, agglutinin (lectin) of Helix 
pomatia is used for histochemical diagnostic to pre­
dict metastasizing of breast cancer [5]. It was shown 
experimentally that expression of agglutinin of Helix 
pomatia is associated with a high risk of metastasizing 
and the unfavorable prognosis [6].
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The aim: To isolate lectins from an albumen gland 
and mucus of Helix pomatia and to investigate their 
potential for creation of an anticancer vaccine or a test­
system for monitoring the efficacy of anticancer 
chemo­ and/or immunotherapy.
Methods: A protein from the Albumen gland 
homogenate and mucus of Helix pomatia was salted 
out. We have got the protein with the concentra­
tion of the 3.11 mg/ml of the Albumen gland and 
4.79 mg/ml of the mucus. 15 different proteins 
(11–150 kDa) were detected from the Albumen gland, 
and 12 (17–146 kDa) — from the mucus, respectively 
by western blotting. Lectins from the Albumen gland 
and mucus showed high agglutination properties with 
rabbit red blood cells. A cross­reactivity of lectins was 
studied using ELISA.
Results: An cytotoxic effect was assessed in vitro 
using the culture of Erlich carcinoma. We did not ob­
serve the cytotoxic effect of lectins on tumor cells. The 
antitumor activity of lectins was studied in vivo in the 
female Wistar rats with transplanted Walker’s carcino­
sarcoma. Rats got injection of lectin in the doses 
of 1 mg/kg of body weight on days 3, 4, 9 and 15 after 
transplantation. Lectins did not demonstrate antitumor 
activity.
For detection of a cross­reactivity between lectins 
of Helix pomatia and antigens of Walker carcinosarco­
ma, we used blood serum of rats, at the different time 
of the tumor growth, and intact rats as a control. We ob­
served the cross­reaction of lectins with the blood 
serum of all rats. For Western­Blot analysis of protein 
from Albumen gland and mucus, we used antibody 
from blood serum, which we used for ELISA. We found 
that the cross­reacting protein has a molecular weight 
of approximately 82 kDa in a pool of proteins isolated 
from the Albumen gland. The cross­reacting protein 
of a pool of the mucus proteins has the molecular 
weight about 68 kDa.
Conclusions: We isolated two pools of lectins 
from the Albumen gland and mucus of Helix pomatia. 
These lectins showed the high agglutination activity 
with rabbit erythrocytes. Neither pool demonstrated 
cytotoxic effect on tumor in vivo and in vitro. Lectins 
from the Albumen gland and from mucus showed 
cross­reactivity with antigens from the blood serum 
of rats with transplanted Walker carcino­sarcoma and 
with blood serum of intact rats. Probably, these lectins 
can be used as a vehicle for tumor vaccines.
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